Genetic modification of stem cells to produce T cells with multiple T cell receptors

By genetically modifying HSCs to introduce multiple TCRs and CARs, the method addresses inefficiencies in T cell production, resulting in multi-TCR T cells with enhanced therapeutic efficacy and flexibility for allogeneic therapies.

JP2024541859APending Publication Date: 2024-11-13アッピア バイオインコーポレイティド
View PDF 5 Cites 0 Cited by

Patent Information

Application Number
JP2024523117
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2021-10-14
Filing Date
2022-10-13
Publication Date
2024-11-13

AI Technical Summary

Technical Problem

Current methods for generating T cells with multiple T cell receptors (TCRs) are inefficient and lead to exhaustion or senescence, limiting their therapeutic efficacy and persistence in vivo, particularly in allogeneic cell therapies.

Method used

A method for generating T cells with multiple TCRs and/or chimeric antigen receptors (CARs) by genetically modifying hematopoietic stem cells (HSCs), allowing for the introduction of additional TCRs after differentiation, reducing the risk of mispairing and enabling rapid, large-scale production of multi-TCR T cells with enhanced cancer cell targeting properties.

Benefits of technology

The method produces homogeneous, ready-made T cells with improved therapeutic efficacy and flexibility, capable of targeting multiple antigens, reducing manufacturing time, and minimizing phenotypic changes, suitable for allogeneic cell therapies.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024541859000001_ABST
    Figure 2024541859000001_ABST
Patent Text Reader

Abstract

The present disclosure provides a method for generating multi-TCR T cells with enhanced anti-tumor phenotype. The T cells are generated from hematopoietic stem cells by introducing a first TCR into the hematopoietic stem cells, followed by introduction of a second TCR.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present disclosure relates to methods for genetically modifying stem cells with multiple T cell receptors. [Background technology]

[0002] In vitro generation and expansion of T cells is useful in a wide range of clinical applications, including cancer therapy. For example, clinical data show that genetically modified T cells with tumor antigen-specific receptors are useful for inducing the regression of metastatic cancer in some patients. Unfortunately, not all patients benefit from such treatment. One reason is that some T cells become exhausted or senescent during in vitro expansion, limiting their therapeutic efficacy and persistence in vivo. Summary of the Invention

[0003] The present disclosure provides systems and methods for rapidly and efficiently generating large numbers of T cells with at least two different T cell receptors (TCRs) and / or chimeric antigen receptors (CARs). By generating T cells with multiple different TCRs (multi-TCR T cells), the methods of the invention can generate T cells that recognize multiple different antigens, thereby improving the efficacy of the T cells as a therapeutic treatment. Similarly, the present invention provides methods for generating T cells that co-express different TCRs, or TCRs and CARs, resulting in an optimal phenotype for the cells that confers specific cancer cell targeting properties.

[0004] In certain embodiments, the present disclosure provides methods of generating multi-TCR T cells from stem cells, e.g., hematopoietic stem cells (HSCs). By starting with HSCs, the systems and methods of the invention exploit the self-renewal and cell differentiation potential of stem cells in the production of the T cells of the invention.

[0005] The advantages of using stem cells (e.g., HSCs) in the methods of the present invention include their regenerative and proliferative potential. Allogeneic cell therapy often requires billions of cells for a single dose of therapy. Because stem cells have a potentially unlimited proliferation capacity, the methods of the present invention are well suited to generate high-quality cell products at large scale and to make these products rapidly available for therapy. Furthermore, a distinguishing feature of stem cells is their ability to differentiate into different cell types. In the context of the present disclosure, the differentiation potential provides a cell manufacturing platform that can generate a wide range of T cell subtypes, including, for example, natural killer T cells, alpha beta T cells, gamma delta T cells, among others.

[0006] In certain embodiments, the methods of the invention include generating genetically modified T cells from HSCs by introducing a transgene encoding at least a first TCR. The HSCs differentiate into T cells expressing the TCR. After differentiation, the T cells may be subjected to one or more selection, maturation, expansion, and / or cryopreservation steps. Before or after any of these aforementioned steps, one or more different TCRs / CARs can be introduced into the T cells (e.g., via introduction of a transgene), thereby generating genetically modified T cells with multiple different TCRs and / or TCRs and CARs.

[0007] The ability to add a desired TCR / CAR to T cells derived from HSCs confers several advantages to the methods of the invention. For example, in certain methods of the invention, HSCs are differentiated into T cells. These T cells can be matured, selected, expanded, and / or cryopreserved. Generally, the steps of this process take about 2-4 weeks in total. Using the methods of the invention, one or more additional TCR / CARs can be introduced into the T cells after differentiation, and optionally after selection, maturation, expansion, and / or cryopreservation.

[0008] Adding additional TCR(s) after differentiation allows one to start with pre-made HSC-derived genetically modified T cells and genetically modify T cells with receptors that target antigens specific to a pathology, e.g., cancer. This can shorten the lead time required to generate T cells with a desired combination of TCR(s) and / or CARs, as additional receptors can be added after the 2-4 week period used to generate single receptor T cells.

[0009] In addition, by adding additional TCR(s) or CARs after the first TCR, the method of the invention may avoid the risk of transcriptional and phenotypic changes of T cells due to long-term culture while expressing multiple different introduced receptors. Furthermore, by having differentiated T cells ready to accept additions, the method of the invention provides greater flexibility to generate multi-TCR T cells with minimal TCR mispairing. TCR mispairing is a phenomenon in which the α or β chain of an endogenous or introduced TCR mispairs with the α or β chain of another introduced TCR. This results in, for example, reduced surface expression of the introduced TCR(s). By using the method of the invention, the first introduced TCR can be genetically modified to reduce the likelihood of mispairing with the second introduced TCR, for example, using modifications such as mouse constant domains, disulfide bridges, etc. Alternatively or additionally, the first introduced TCR can be a gamma delta (γδ) TCR and the second introduced TCR an alpha beta (αβ), which also reduces the likelihood of mispairing.

[0010] Thus, the present invention provides a platform for generating allogeneic, preformed, non-HLA-restricted NKT or γδ T cells that can be cryopreserved and subsequently thawed for use. These cells can then be further genetically modified in a patient-specific manner, for example by the introduction of a CAR or TCR that targets a particular pathology. Thus, the stem cell cultures and compositions of the present invention can be used to treat thousands of different patients across a myriad of pathologies.

[0011] The present invention provides methods for generating genetically modified T cells. An exemplary method includes performing a process of in vitro differentiation of hematopoietic stem cells (HSCs) to generate allogeneic gamma delta (γδ) T cells or invariant natural killer T (iNKT) cells that contain a first T cell receptor (TCR) that is not HLA restricted. The method further includes introducing at least a second TCR into the γδ T cells or iNKT cells to generate T cells with two distinct TCRs. In certain embodiments, the second or additional TCR can be HLA restricted or patient specific.

[0012] In certain embodiments, the method also includes maturing the T cells after introducing at least a second TCR into the γδ T cells or iNKT cells.

[0013] In some methods of the present invention, HSCs are differentiated into γδ T cells. In certain embodiments, the second TCR is alpha beta (αβ) TCR. In some methods of the present invention, HSCs are differentiated into iNKT cells. In certain embodiments, the second TCR is alpha beta (αβ) TCR.

[0014] In certain methods, the in vitro differentiation step comprises introducing one or more nucleic acids encoding a first T cell receptor into the HSCs. Introducing a second TCR may comprise introducing one or more nucleic acids encoding a second T cell receptor into the γδ T cells or iNKT cells.

[0015] The in vitro differentiation step may further comprise introducing one or more nucleic acids encoding at least one of a chimeric antigen receptor (CAR) and one or more transgenes. In certain embodiments, the at least one or more transgenes comprise at least one of a cytokine, a checkpoint inhibitor, an inhibitor of transforming growth factor beta signaling, an inhibitor of cytokine release syndrome, an inhibitor of neurotoxicity, or other payload to render the T cells more potent or less susceptible to exhaustion or rejection.

[0016] In certain methods of the present invention, the first and / or second TCR is a genetically modified TCR. In certain embodiments, the first TCR is a genetically modified TCR. In certain embodiments, the second TCR is a genetically modified TCR. The genetically modified TCR according to the present invention may include one or more modifications to prevent TCR mispairing between the first TCR and the second TCR. Exemplary modifications include one or more of mouse constant domains, disulfide bridges, and other dimerization domains.

[0017] In certain methods, the HSCs are derived from progenitor cells, such as pluripotent stem cells. Thus, the in vitro process may further include genetic editing of the HSCs or progenitor cells to make the T cells more potent or less susceptible to exhaustion or rejection.

[0018] In exemplary methods, the second TCR is directed against a cancer germline antigen, a viral antigen, or a tumor-specific neo-antigen.

[0019] In certain embodiments, the step of introducing at least a second TCR comprises introducing a plurality of different TCRs. Each different TCR may be directed to a different tumor-specific neo-antigen. The neo-antigen-reactive TCRs may be obtained or derived from peripheral blood T cells or tumor-infiltrating lymphocytes.

[0020] In certain exemplary methods, the step of introducing the second TCR comprises transferring one or more nucleic acids into the γδ T cell or iNKT cell via retroviral transduction, lentiviral transduction, or non-viral methodologies of nucleotide transfer.

[0021] In certain embodiments, the method further comprises in vitro activation and expansion of the T cells using HLA-matched or partially matched PBMC carrying a peptide recognized by the second TCR.

[0022] The disclosed invention also provides a method of treatment using the multi-TCR cells of the present invention. An exemplary method of treatment includes obtaining HSCs and performing a process of in vitro differentiation of the HSCs into γδ T cells or iNKT cells, where the differentiated T cells include a first TCR. The method may also include introducing at least a second TCR into the γδ T cells or iNKT cells, and maturing the resulting T cells to generate T cells with two distinct functional TCRs. The method then includes introducing the T cells into a subject, where the at least the second TCR is directed against a disease-associated antigen expressed on the surface of a cell in the subject.

[0023] In certain embodiments, the HSCs are obtained or derived from a subject.

[0024] In an exemplary method, the method further comprises, after performing the in vitro differentiation step, obtaining data identifying one or more TCRs that target a disease-associated antigen, and subsequently performing a step of introducing at least a second TCR. [Brief description of the drawings]

[0025] [Figure 1] FIG. 1 shows a method for generating multi-TCR T cells.

[0026] [Diagram 2] FIG. 1 shows the steps of ex vivo T cell production by three different processes.

[0027] [Diagram 3] FIG. 1 shows a comparison of two processes for generating T cells in vitro.

[0028] [Figure 4] FIG. 1 shows the general steps of the method of the invention for generating multi-TCR T cells from HSCs.

[0029] [Diagram 5]FIG. 1 shows the general steps of the method of the invention for generating multi-TCR T cells from HSCs.

[0030] [Figure 6] FIG. 1 shows the general steps of the method of the invention for generating multi-TCR T cells from HSCs.

[0031] [Figure 7] FIG. 1 shows a comparison of PBMC cell lines for expanding / activating multi-TCR T cells.

[0032] [Figure 8] FIG. 1 shows the results of expanding multi-TCR T cells in the presence of antigen-presenting PBMC.

[0033] [Figure 9] FIG. 1 shows generation of antigen-presenting target cell lines.

[0034] [Figure 10] FIG. 1 shows the cytotoxic potency of multi-TCR T cells generated using the methods of the invention.

[0035] [Figure 11] FIG. 1 shows the cytotoxic potency of multi-TCR T cells generated using the methods of the invention. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0036] Clinical studies of chimeric antigen receptor (CAR) T cells have shown remarkable results in the treatment of certain pathologies, such as B-cell malignancies. However, currently, commercial approaches involving CAR T cell therapy involve autologous CAR T cells, the widespread use of which is limited by the logistics and high costs associated with ad hoc generation. Allogeneic CAR T cell therapy addresses the limitations of autologous cells by providing pre-made cell stocks that are immediately available for use in treating patients. However, despite their potential, methods for consistently generating therapeutically effective allogeneic CAR T cells have not been established. Most protocols require, for example, long-term ex vivo culture with at least two activation steps, which can lead to hyperdifferentiation, T cell exhaustion, and / or cellular senescence, compromising in vivo efficacy. See Jafarzadeh, 2020, Prolonged Persistence of Chimeric Antigen Receptor (CAR) T Cell in Adoptive Cancer Immunotherapy: Challenges and Ways Forward, Frontiers in Immunology, 11(702):1-17, incorporated by reference.

[0037] The present disclosure provides a reliable method for producing T cells with improved phenotype and cell function from stem cells (e.g., hematopoietic stem cells) by the introduction of at least two unique T cell receptors (TCRs). The present disclosure provides a method for rapid and efficient production of large numbers of multi-TCR T cells. Furthermore, TCRs can be added at different points during the production process. Thus, in certain embodiments of the present invention, T cells can be generated from hematopoietic stem cells and then subjected to expansion, maturation, and / or storage steps. These T cells can be a ready-made starting point into which one or more additional TCRs can be introduced. If necessary, specific additional TCRs targeting distinct antigens required to treat different diseases in different patients can be introduced into the cells.

[0038] Certain preferred methods of the invention involve introducing a first TCR into hematopoietic stem cells (HSCs) and differentiating the cells into gamma delta (γδ) T cells or invariant natural killer T (iNKT) cells. One or more distinct additional TCRs are then introduced into the T cells to generate T cells with at least two distinct TCRs.

[0039] Differentiation of HSCs into γδ or iNKT provides several advantages to the methods of the disclosure.

[0040] For example, certain methods involve modifying stem cells (such as HSCs) to function as invariant NKT cells that have been genetically altered to have one or more characteristics that make the cells suitable for universal off-the-shelf use (e.g., prepared for individuals other than the individual from which the original cells were obtained) without eliciting an adverse immune response in the recipient of the cells.

[0041] iNKT cells are a small subpopulation of T lymphocytes that have several characteristics that make them useful for established cell therapies, such as cancer therapy. iNKT cells have a remarkable ability to target multiple types of cancer, independent of tumor antigens and MHC restriction. iNKT cells recognize glycolipid antigens and therefore are not MHC restricted. Although the natural ligands of iNKT cells have not yet been fully identified, iNKT cells appear to be able to recognize certain conserved glycolipid antigens derived from many tumor tissues.

[0042] Furthermore, iNKT cells contain several mechanisms that are useful for targeting and attacking tumor cells. iNKT cells remain dormant before stimulation, but upon stimulation, they rapidly produce large amounts of cytokines that activate the cells to kill tumor target cells. Furthermore, iNKT cell-induced antitumor immunity can effectively target multiple types of cancers regardless of tumor antigen and MHC restriction, thereby effectively preventing tumor immune escape and minimizing the possibility of tumor recurrence.

[0043] At the same time, iNKT cells do not recognize mismatched MHC molecules and protein self-antigens and therefore do not cause graft-versus-host disease (GvHD). Similarly, iNKT cells can be genetically modified to avoid host-versus-graft (HvG) depletion. The availability of powerful gene editing tools (e.g., CRISPR-Cas9 systems) allows iNKT cells to be genetically engineered to be resistant to targeted depletion of host immune cells. iNKT cells also appear to be intrinsically resistant to allogeneic NK cell killing.

[0044] iNKT cells are also strongly associated with cancer. In humans, iNKT cell abundance is decreased in patients with solid and hematological cancers, whereas increased numbers of iNKT cells indicate improved prognosis. Thus, iNKT cells, when generated using the methods of the present invention, may serve as an effective "off-the-shelf" cell product for the treatment of various diseases, depending on the introduced TCR. Allowing for the transfer of sufficient iNKT cells to patients in multiple doses may provide patients with the best opportunity to harness the full potential of iNKT cells to fight disease.

[0045] Similar to iNKT cells, γδ T cells also form a relatively small subset of T lymphocytes in the peripheral blood of adults. γδ T cells typically account for anywhere between 1% and 10% of CD3-positive T cells in human blood. However, unlike conventional T cells that express αβ TCRs that recognize antigen-derived peptides carried by MHC molecules, γδ T cells typically recognize target antigens independent of antigen processing and MHC / HLA restriction. γδ T cells share traits of the adaptive immune system (e.g., expression of clonally rearranged TCR genes). At the same time, γδ T cells are similar to innate immune cells and lack the requirement for antigen processing to activate effector functions. Thus, γδ T cells respond rapidly to TCR stimulation.

[0046] Activated γδ T cells can lyse various types of solid tumors and other malignancies and produce many cytokines. In addition to the TCR, γδ T cells can also express additional activating receptors. For example, γδ T cells often co-express functional receptors of innate immune cells, e.g., activating natural killer (NK) receptors such as NKG2D, NKp30, and / or NKp44, which induce cytotoxic effects. Thus, γδ T cells have two independent recognition pathways to sense stressed and malignant cells.

[0047] Furthermore, in vitro activated cells isolated from peripheral blood demonstrate potent and HLA-independent activity of γδ T cells against a variety of solid tumor and leukemia / lymphoma cells.

[0048] Thus, the present disclosure provides methods of generating T cells using stem cells by introducing a first TCR into hematopoietic stem cells (HSCs) and differentiating the cells into gamma delta (γδ) T cells or invariant natural killer T (iNKT) cells. One or more distinct additional TCRs are subsequently introduced into the T cells to generate T cells with at least two distinct TCRs, generating T cells with enhanced anti-tumor activity.

[0049] The present disclosure further provides systems and methods for generating T cells incorporating multiple transgenes, including TCRs, chimeric antigen receptors (CARs), and / or at least one additional transgene, from stem cells (e.g., HSCs). By initiating the generation process from stem cells, the systems and methods of the present disclosure exploit the self-renewal and cell differentiation capabilities for the production of T cells with a "younger" phenotype and enhanced anti-tumor activity. In particular, the present disclosure provides for introducing a nucleic acid encoding at least one TCR into CD34-positive stem cells, followed by the introduction of at least one additional TCR. Due to the combined expression of multiple TCRs (and optionally any introduced CAR and additional transgene(s)), T cells generated using the methods of the present disclosure have specific cancer cell targeting properties useful for the treatment of cancer.

[0050] FIG. 1 shows a general overview of the method of the present disclosure for generating multi-TCR T cells. As shown in FIG. 1, the process starts with the introduction of a first TCR into stem cells (e.g., HSCs). Thus, the stem cells are differentiated into T cells, preferably γδ T cells, iNKT cells. Surprisingly, the inventors have discovered that the method of the present disclosure offers unique flexibility when a second TCR is introduced into the differentiated T cells. As shown, the second TCR can be introduced early in the manufacturing process, such as before maturation of the T cells. Alternatively, the second TCR can be introduced at an intermediate point in the process, such as before or during expansion of the T cells. The method disclosed herein also contemplates providing a second TCR after expansion, and potentially even after cryopreservation, activation, and expansion steps. Thus, the method of the present disclosure allows for the generation of large numbers of T cells from HSCs, maintaining the cells in culture or cryopreservation, and introducing into the cells the second antigen-specific TCR required according to the patient's needs. Thus, the methods of the present disclosure allow for the generation of multi-TCR T cells with reduced production time.

[0051] The disclosed methods and systems may also incorporate a step of generating initial T cells, i.e., T cells prior to introduction of a second TCR, using a shortened ex vivo culture time compared to previous methods. Certain methods of the invention shorten the ex vivo culture by omitting one or more ex vivo activation steps used in conventional T cell differentiation methods, thereby shortening the ex vivo manufacturing process by up to 2-3 weeks. Other methods of the invention provide a single activation step. The methods of the invention recognize that a lengthy activation and / or proliferation process may occur in vivo after administration to a subject. By shortening the ex vivo cell culture, the methods of the invention minimize the opportunity for transcriptional and / or phenotypic changes to occur during T cell generation. Additionally, shortening the ex vivo culture time reduces the amount of expensive cell culture consumables required for T cell maintenance.

[0052] In different aspects, the present disclosure provides a multi-step workflow for generating a T cell product with a single activation step. A particular method involves performing a process that includes in vitro differentiation and maturation of HSCs into multi-TCR T cells with only one in vitro T cell activation step. The resulting multi-TCR T cell product can be used for therapy or research. Conventional methods of T cell manufacturing require at least two separate in vitro T cell activation steps. Multiple activation steps generally involve multiple media types, i.e., media containing different activation factors. Advantageously, generation of T cells with a single activation step reduces cell culture time and generates a more effective T cell product with less expression of markers associated with T cell exhaustion.

[0053] The methods of the invention are useful for generating multi-TCR T cell products with less in vitro cell culture. By shortening the in vitro cell culture, the methods of the invention generate T cell products that are more effective and contain fewer exhausted / dysfunctional T cells. The T cell products may express proteins involved in T cell exhaustion, e.g., PD-1, CTLA-4, LAG-3, TIM-3, 2B4 / CD244 / SLAMF4, CD160, TIGIT, at lower levels than T cells generated by two or more T cell activation steps. The T cell products may also express higher levels of IL-2.

[0054] Certain embodiments include a multi-step process for generating multi-TCR T cells or early T cells (before the introduction of a second TCR), where only one of the steps is a T cell activation step. The single activation step can be performed by culturing the T cells in an activation medium, e.g., a medium containing a T cell activation reagent such as an antibody.

[0055] In some examples, the activation step includes peripheral blood mononuclear cell (PMBC)-based activation. PMBC-based activation may include introducing T cells into alpha-galactosylceramide (aGC)-loaded PBMCs, soluble anti-CD3 / 28 positive PBMCs, and soluble anti-CD2 / 3 / 28 positive PBMCs. In some examples, the activation step includes an antigen-presenting cell (aAPC)-based T cell activation step. Thus, the activation step may include introducing T cells into aAPCs. Preferably, the aAPCs are irradiated. The aAPCs may be genetically modified K562 cells expressing CD80-CD83-CD137L-CAR antigens. The aAPCs may be aAPC+CD1d and / or aAPC+CD1d+ / -aGC. In other examples, the activation step includes a feeder-free-based T cell activation step. The feeder-free based T cell activation step may include introducing soluble antibodies to the T cells, including anti-CD3, anti-CD28, anti-CD2 / 3 / 28, CD3 / 28. In some embodiments, the method includes culture medium including one or more of IL-7 / 15, IL-2, IL-2+21, IL-12, or IL-18. In some embodiments, the medium contains IL-15.

[0056] In certain embodiments, the method of the present invention comprises obtaining stem cells into which at least a first TCR has been introduced. The method may comprise obtaining stem cells (e.g., CD34+ hematopoietic stem / progenitor cells); introducing one or more nucleic acids (e.g., a first TCR, and optionally one or more additional TCRs, nucleic acids encoding CARs, and / or additional transgenes) into the stem cells. After introduction of the first TCR, the method further comprises performing in vitro differentiation and maturation of the stem cells to generate T cells. As described in FIG. 1, at least a second TCR can be introduced at various times during the differentiation and maturation steps. After introduction of at least a second TCR, the multi-TCR T cells can be used (e.g., for allogeneic therapy or research) or stored. In certain embodiments, the method comprises performing a single in vitro activation step or no in vitro activation step.

[0057] Certain methods of the invention require obtaining stem cells. Preferably, the cells are CD34+ cells. In one non-limiting example, the CD34+ stem cells are hematopoietic stem / progenitor cells. Hematopoietic stem or progenitor cells are stem cells that give rise to other blood cells in a process called hematopoiesis.

[0058] Hematopoietic stem / progenitor cells can be obtained from healthy donors. Hematopoietic stem / progenitor cells can be obtained, for example, from bone marrow, peripheral blood, amniotic fluid, or umbilical cord blood. Hematopoietic stem / progenitor cells can be obtained from umbilical cord blood by clamping both ends of the umbilical cord and aspirating blood with a needle between the clamped ends. Hematopoietic stem / progenitor cells can be isolated from umbilical cord blood using positive immunomagnetic separation techniques, and citrate-phosphate-dextrose (CPD) can be added to the umbilical cord blood as an anticoagulant. Cells obtained from umbilical cord blood can be cryopreserved and stored at a temperature of, for example, -80 degrees Celsius until use.

[0059] In the practice of the disclosed methods, obtaining stem cells preferably includes receiving a vial of cryopreserved CD34+ cord blood cells that contain hematopoietic stem / progenitor cells. The vial of cryopreserved cord blood cells can be received from a cell bank, for example, in an insulated container on dry ice.

[0060] A vial of cryopreserved cord blood cells can be thawed according to methods known in the art. For example, the cell vial can be thawed by placing it in a 37° C. water bath for about 1-2 minutes. In some preferred embodiments, once the cells are thawed, they are plated onto tissue culture dishes that have been precoated with a reagent that promotes co-localization of the virus with target cells to enhance transduction efficiency.

[0061] CD34+ cells can be plated in a standard 6-well dish at, for example, 10,000 cells / well, 15,000 cells / well, or 20,000 cells / well, or 25,000 cells / well, or more. Preferably, the cells are plated at 15,000 cells / well.

[0062] The method may further comprise introducing into the CD34+ stem cells one or more nucleic acids encoding the first TCR and optionally one or more CARs, and / or additional transgenes. The method may then further comprise introducing a second nucleic acid(s) encoding at least a second distinct TCR. In some embodiments, the introduced TCR generates T cells capable of targeting a specific protein expressed on the surface of the cancer cells.

[0063] In a preferred embodiment, one or more of the TCRs introduced are introduced by a nucleic acid encoding an iNKT TCR. The iNKT TCR may include one of the alpha chain of the iNKT cell receptor, the beta chain of the iNKT cell receptor, or both. Preferably, the iNKT cell receptor is expressed by the stem cell such that the stem cell recognizes alpha-galactosylceramide. In another preferred embodiment, one or more of the TCRs introduced are introduced by a nucleic acid encoding a delta gamma T cell TCR. The TCR may include one of the gamma chain of the TCR, the delta chain of the TCR, or both.

[0064] The T cells generated by the method of the invention may be genetically modified to express at least one additional transgene other than the transgene encoding the introduced TCR. The transgene may be, for example, one of a cytokine, a checkpoint inhibitor, an inhibitor of transforming growth factor beta signaling, an inhibitor of cytokine release syndrome, or an inhibitor of neurotoxicity. Thus, the method of the invention may be useful for generating multi-TCR T cells with enhanced effector function.

[0065] For example, in some instances, the methods of the invention are useful for producing CAR T cells with improved proliferation and persistence capabilities, resulting from the introduction of transgenes encoding one or more of IL-2, IL-7, IL-1-15. In some instances, the methods may provide CAR T cells with increased IFN-g production, and thus improved T cell potency, for example, by the introduction of transgenes encoding one or more of IL-12, IL-18. In some instances, the methods of the invention are useful for enhancing naive T cell generation by introducing a transgene including IL-21. In some instances, the methods described herein provide for the generation of CAR T cells with improved safety profiles, for example, by introducing inhibitors of IL-6, GM-CSF, or other mediators of cytokine release syndrome and neurotoxicity. The methods may provide CAR T cells with improved potency, for example, by providing a payload useful for combating the tumor microenvironment, via inhibitors of the TGF-B checkpoint.

[0066] Introducing one or more nucleic acids into stem cells can be accomplished by viral transduction or non-viral transfection. In some instances, for example, the method of introducing one or more nucleic acids includes a non-viral method, for example, using the Sleeping Beauty transposon / transposase system. The Sleeping Beauty transposon system includes a synthetic DNA transposon designed to introduce a precisely defined DNA sequence into the chromosome of a cell. This system uses a Tc1 / mariner type system in which the transposase has been resurrected from multiple inactive fish sequences. Advantageously, non-viral methods can provide the benefit of reduced costs and reduce the risks associated with the use of certain viruses. However, non-viral methods may involve reduced efficiency. Thus, in a preferred embodiment, nucleic acids are introduced into stem cells by viral transduction, for example, via retrovirus.

[0067] Viral transduction methods are well recognized for their versatility and include the use of lentiviral vectors, which are useful for transducing significant amounts of nucleic acid into both dividing and non-dividing cells. The use of lentiviral vectors is considered safe and often results in long-term transgene expression. Thus, the method 101 preferably introduces one or more nucleic acids into 34+ stem cells (109) via lentiviral transduction. For a discussion of lentiviral transduction of stem cells, see Jang, 2020, Optimizing lentiviral vector transduction of hematopoietic stem cells for gene therapy, Gene Therapy (27):545-556, which is incorporated by reference.

[0068] The method of the present invention is not limited by any one process or experimental procedure for introducing nucleic acid into stem cells. In some examples, a single lentiviral vector is used. A single lentiviral vector can code for each of TCR, CAR, and additional transgenes. In other examples, at least two separate lentiviral vectors are used, each of the at least two lentiviral vectors coding for at least one of TCR, CAR, and additional transgenes, so that upon transduction, each of TCR, CAR, and additional transgenes is transduced into stem cells. Furthermore, when two or more lentiviral vectors are used, the method is not limited by the temporal order of introducing two (or more) lentiviral vectors into stem cells. The vectors may be introduced simultaneously or sequentially in the same transduction.

[0069] In certain embodiments, the methods of the invention further comprise performing a process comprising in vitro differentiation and maturation of stem cells (eg, HSCs) into T cells.

[0070] One advantage of the cell manufacturing method disclosed herein is the ability to generate a wide range of T cell subtypes from a single starting material, i.e., stem cells. The T cells generated by the method of the present invention may include, for example, helper T cells, cytotoxic T cells, memory T cells, regulatory T cells, natural killer T cells, invariant natural killer T cells, alpha beta T cells, and gamma delta T cells. In a preferred embodiment, the method 101 includes generating invariant natural killer T cells. The generation of invariant natural killer T (iNKT) cells and gamma delta T cells is preferred for allogeneic cell therapy applications, particularly the ability to activate and expand antigen-specific T cell responses for treating cancer without inducing graft-versus-host disease.

[0071] Thus, the methods of the invention may include performing an in vitro differentiation and maturation process of stem cells (e.g., HSCs) into T cells (e.g., iNKT or γδ T cells). As discussed in detail below, performing in vitro differentiation and maturation of stem cells may be accomplished provided that the process does not include a subsequent in vitro step of T cell activation and proliferation.

[0072] Differentiation of CD34 positive cells into T cells can occur in stages. The first stage can include in vitro differentiation of CD34 positive stem cells into CD4 and CD8 double negative T cells. Differentiation of CD34 positive stem cells generally involves introducing CD34 positive stem cells into a combination of cytokines and / or chemokines during, for example, 1-2 weeks of culture. In some instances, the cytokines and / or chemokines can be provided by a commercially available progenitor cell growth supplement, such as the supplement sold under the trade name StemSpan by STEMCELL. An embodiment performing an in vitro process further includes maturation of CD4 and CD8 double negative T cells into CD4 and CD8 double positive cells. In some instances, maturing the double negative cells includes culturing the cells in a commercially available progenitor maturation medium, such as the progenitor maturation medium sold under the trade name StemSpan by STEMCELL. In some embodiments, the cells are cultured in the progenitor maturation medium for 7 days.

[0073] In certain embodiments, CD4+CD8+ T cells are generated by performing an in vitro differentiation and maturation process of CD34+ stem cells into T cells. The CD4+CD8+ T cells can be naive T cells. Naive T cells are generally characterized by surface expression of L-selectin (CD62L) and CC chemokine receptor type 7 (CCR7). In some instances, the absence of activation markers CD25, CD44, or CD69, and the absence of memory CD45RO isoforms. Naive T cells may also express a functional IL-7 receptor consisting of subunits IL-7 receptor alpha, CD127, and common gamma chain, CD132. Naive T cells may be cryopreserved for storage or introduced into a subject during allogeneic cell therapy. In certain embodiments, the naive T cells only contain a first TCR receptor, and a second TCR receptor is introduced before / after cryopreservation or use in allogeneic cell therapy. In the subject's body, naive T cells can circulate through peripheral lymphatics and await the first antigenic stimulation. Upon receiving the first stimulation via the TCR of the naive cell, the cell begins to regulate the expression of surface molecules associated with activation, co-stimulation, and adhesion. The expression pattern of these molecules and / or the second introduced TCR can be used to further define the effector and antigenic experience of the T cell subset.

[0074] In some embodiments, CD4+CD8+ T cells are expanded in vitro prior to cryopreservation and / or administration to an allogeneic cell therapy recipient. The expansion of CD4+CD8+ T cells may include culturing the cells in the presence of one or more of IL-7, IL-15, CD3, CD28, CD2, alpha-galactosylceramide. In certain aspects, T cells are expanded in vitro prior to the introduction of the second TCR. Alternatively, T cells may be expanded in vitro after the introduction of the second TCR. In certain methods, T cells may be expanded in vitro prior to and after the introduction of the second TCR.

[0075] Certain methods of the present invention utilize an in vivo activation mechanism, thereby reducing the necessary in vitro culture step used in conventional methods. When multi-TCR T cells are generated and introduced into the subject's body without undergoing two activation steps, the T cells are fully activated when they encounter appropriately activated antigen-presenting cells (APCs), such as dendritic cells, for example in secondary lymphoid organs. If the APC presents an appropriate peptide ligand via a major histocompatibility complex (MHC) class II molecule, it will be recognized by one or more of the introduced TCRs. This interaction is important for activating the T cells.

[0076] Two other stimulatory signals delivered by APCs may also be required. These signals can be provided by two different ligands on the APC surface, e.g., CD80 and CD86, to surface molecules on T cells, e.g., CD28. Other factors important for activation include factors involved in inducing T cells to differentiate into various subsets of effector T cells, e.g., cytokines (e.g., IL-6, IL-12, and TGF-β). CD28-dependent costimulation of activated T cells can lead to the production of IL-2 by the activated T cells themselves. Expression of IL-2 can be followed by upregulation of the third component of the IL-2 receptor, also known as CD25 (called the α chain), in addition to other regulatory molecules such as ICOS and CD40L. Binding of IL-2 to the high affinity receptor promotes cell proliferation, and APCs, mainly dendritic cells, produce various cytokines or express surface proteins that induce differentiation of CD4+ T lymphocytes into cytokine-producing effector cells, depending on environmental conditions.

[0077] Figure 2 shows three ex vivo T cell production process steps starting with HSCs. These illustrated processes involve the introduction of a first TCR to generate T cells, preferably iNKT or γδ T cells, from HSCs. As shown in Figure 1, the flexible method of the invention allows for the introduction of a second TCR at various time points.

[0078] In Figure 2, the top process 203 represents a conventional ex vivo process for generating T cells from HSCs. In contrast, ex vivo processes 205 and 207 show steps used in the ex vivo process of the present invention to generate T cells more quickly and with fewer steps.

[0079] In a conventional process 203, mature T cells are subjected to at least two in vitro activation steps. This process 203 requires at least 35 days of ex vivo cell culture, and may require longer culture (often exceeding 42 days, and often longer).

[0080] Conversely, the process 205 of the present invention omits all ex vivo T cell activation steps. Thus, the present method 205 can generate T cells in as little as 21 days. By omitting the ex vivo activation step, this process for producing T cells using ex vivo culture starting from HSCs takes substantially less time than the conventional process 203. Thus, rather than the 35-42 days or more required for the conventional process 203, the process 205 of the present invention can generate therapeutically usable T cells in as little as 21 days.

[0081] FIG. 2 illustrates another process 207 of the invention for generating T cells from HSCs. As shown, this process 207 includes a single ex vivo activation step. Thus, this process of the invention also represents an improvement over the conventional process 203 for producing T cells from HSCs. Using a single activation step, the process of the invention for producing T cells can generate allogeneic T cells, including multi-TCR T cells, in about 28-31 days. These methods can achieve the advantages that a particular activation step has for a particular type of T cell, TCR, combination of multiple TCRs, and / or T cell therapy in less time than conventional processes for generating single TCR T cells. For example, a single activation step can be useful to generate an effective amount of T cells to ensure that T cells introduced with a second TCR, multi-TCR T cells after introduction of a second TCR, and / or T cells are primed to treat and / or expand when introduced into a subject as part of a therapeutic treatment.

[0082] Figure 3 shows a comparison of two processes for generating T cells in vitro. The first process (version 1.0) includes two activation steps. The two-step activation process, achieved by treating double positive T cells with different activation media, e.g., including CD3 / CD28 / CD2 and IL-15, extends the manufacturing process by at least one week, and generally more, than the inventive process disclosed herein. The second process (version 2.0) shown in Figure 3 omits the in vitro activation.

[0083] The method of the present invention may include a single activation step. The single activation step may include culturing the T cells with an activation reagent for a period of 7 days or less. In other embodiments, the single activation step includes culturing the T cells in activation medium for 6, 5, 4, 3, 2, or 1 day or less. In other embodiments, the single activation step includes not culturing the T cells in activation medium for more than 8, 9, 10, 11, 12, 13, or 14 days. The single activation step may include culturing the T cells in a single type of activation medium. The single type of activation medium may include an activation reagent, such as a soluble antibody. The single activation step may include co-culturing the T cells with antigen-presenting cells (e.g., aAPCs). The single activation step may include co-culturing the T cells with PBMCs.

[0084] Preferred methods of the invention include an activation step after introduction of a second TCR into a multi-TCR T cell. Certain methods of the invention include an activation step after introduction of a first TCR into a multi-TCR T cell. Certain methods of the invention include an activation step after introduction of a first and second TCR into a multi-TCR T cell.

[0085] The method of the present invention includes the generation of T cells from hematopoietic stem / progenitor cells. Hematopoietic stem / progenitor cells are generally associated with CD34+ cells that can be found in umbilical cord blood. In some instances, the cells can be derived from progenitor cells. In some instances, the cells are pluripotent stem cells, such as embryonic stem cells.

[0086] Allogeneic CAR T cells generated from HSCs may provide a curative therapeutic approach to certain pathologies. However, there are several limitations, including GVHD, which is a donor T cell-mediated alloreactive process that is responsible for much of the morbidity and mortality associated with allogeneic cell therapy. Several clinical studies have shown that donor iNKT cells can prevent GVHD without increasing the risk of disease recurrence. Adoptive transfer and subsequent in vivo activation and / or expansion of donor CAR iNKT cells may prevent or alleviate symptoms of GVHD. This protective effect may be mediated by Th2 polarization of alloreactive T cells and expansion of donor regulatory T cells (Tregs). Because allogeneic iNKT cells generated by the methods of the present invention do not cause GVHD, the methods described herein provide an ideal platform for "off-the-shelf" CAR immunotherapy.

[0087] The methods of the invention are useful for producing therapeutically active T cells that acquire antigen specificity through functional rearrangement of the antigen recognition region of the TCR. TCR is a molecule found on the surface of T cells (or T lymphocytes) that recognizes antigens bound to major histocompatibility complex molecules. TCRs can be composed of at least two different protein chains (e.g., heterodimers). In most (e.g., 95%) T cells, the TCR consists of an alpha (α) chain and a beta (β) chain, while in some (e.g., 5%) T cells, the TCR consists of a gamma (λ) chain and a delta (δ) chain. Such T cells have antigen specificity in the cell surface TCR molecule and can differentiate in vivo into different phenotypic subsets, including but not limited to classical CD3 positive, alpha-beta (αβ) TCR CD4 positive, CD3 negative αβ TCR CD8 positive, gamma delta (γδ) T cells, natural killer T (NTK) cells, etc. Additionally, T cells may further comprise various activation states, including, but not limited to, naive, central memory, effector memory, terminal effector, and the like.

[0088] In one non-limiting example, T cells can be engineered to express one or more artificial TCRs that direct cytotoxicity against tumor cells. For example, one or more of the artificial TCRs can target a specific neo-antigen. Neo-antigens are generally tumor-specific antigens that arise from tumor cell mutations. Neo-antigens can also arise from viral infection, alternative splicing, and gene rearrangements. Neo-antigens are generally not expressed in normal healthy cells. Thus, neo-antigens provide ideal targets for the subject's genetically engineered immune cells to specifically direct. In certain embodiments, the genetically engineered immune cells of the invention have introduced artificial TCRs that target different neo-antigens. In certain embodiments, the invention provides compositions of genetically engineered cells, where separate populations of cells have different introduced TCRs, each directed to a different neo-antigen.

[0089] In a particular embodiment, the method of the present invention provides for the production of CAR T cells. CAR T cells are genetically engineered T cells with artificial T cell receptors for use in immunotherapy. CARs (i.e., chimeric antigen receptors) can be used to graft the specificity of monoclonal antibodies onto stem cells with TCRs, for example, via the transfer of coding sequences facilitated by retroviral vectors. CARs are receptor proteins genetically engineered to give T cells new abilities to target specific proteins. The receptors are chimeric structures that combine both antigen binding and T cell activation functions in a single receptor. Thus, the method of the present invention provides products for immunotherapy by generating recombinant T cells that contain one or more CARs that recognize cancer cells to more effectively target and destroy them.

[0090] In carrying out the method of the present invention, any CAR suitable for genetically modifying effector cells (e.g., T cells) used in adoptive immunotherapy can be used in the present invention. CARs that can be used in the present invention include those described in Kim and Cho, 2020, Recent Advances in Allogeneic CAR-T Cells, Biomolecules, 10(2):263, which is incorporated by reference.

[0091] CARs generally include an extracellular domain, a transmembrane domain, and an intracellular domain. The extracellular domain may include an antigen binding / recognition region / domain. The antigen binding domain of a CAR is useful for binding to a specific antigen, such as a tumor antigen, a pathogen antigen (e.g., a viral antigen), or a CD (cluster of differentiation) antigen. The extracellular domain may also include a signal peptide that directs the nascent protein to the endoplasmic reticulum. The signal peptide may be essential when the CAR is glycosylated and anchored to the cell membrane. The transmembrane domain is a hydrophobic alpha helix that crosses the membrane. Different transmembrane domains result in different receptor stabilities. After antigen recognition, the receptors cluster and a signal is transmitted to the cell. The most commonly used intracellular component is CD3Xi, which contains three ITAMs. CD3Xi transmits an activation signal to T cells after antigen binding. CARs may also include a spacer region that links the antigen binding domain to the transmembrane domain. The spacer region must be sufficiently flexible to allow the antigen-binding domain to orient in different directions to facilitate antigen recognition. The spacer can be the hinge region of IgG1, or the CH2CH3 region of immunoglobulins and part of CD3.

[0092] Currently, there are three generations of CARs. First generation CARs typically contain an antigen recognition domain (e.g., single chain variable fragment (scFv)) derived from an antibody fused to a transmembrane domain fused to a cytoplasmic signaling domain of a T cell receptor chain. First generation CARs typically have the intracellular domain of the CD3 Xi chain, which is the main mediator of signals from endogenous TCR. First generation CARs can provide de novo antigen recognition in a single fusion molecule, independent of antigen presentation via HLA, and trigger activation of both CD4+ and CD8+ T cells through the CD3 Xi chain signaling domain. Second generation CARs are similar to first generation CARs, but contain two co-stimulatory domains, such as CD28 or 4-1BB. The involvement of these intracellular signaling domains improves T cell proliferation, cytokine secretion, resistance to apoptosis, and persistence in vivo. Third generation CARs combine multiple co-stimulatory domains, such as CD28-41BB or CD28-OX40, to further enhance T cell activity.

[0093] In certain embodiments, the method of producing a multi-TCR T cell of the invention comprises introducing one or more additional transgenes, i.e., transgenes in addition to the first and / or second introduced TCR. For example, the additional transgenes may encode one or more cytokines. Cytokines refer to substances secreted by certain cells of the immune system that affect other cells, such as interferons, interleukins, growth factors, etc. In certain embodiments, transgenes encoding one or more of IL-2, IL-7, IL-15, IL-12, IL-18, or IL-21 are introduced into the cells to promote T cell function, potency, and / or antigen target specificity.

[0094] Introduction of one or more transgenes into multi-TCR T cells may improve properties such as T cell proliferation and persistence (e.g., using IL-2, IL-7 / 15), IFN-g production and T cell potency (e.g., using IL-12, IL-18), enhance naive subsets (e.g., IL-21), improve safety (e.g., via inhibitors of IL-6, GM-CSF or other mediators of CRS and neurotoxicity), or improve efficacy by combating the tumor microenvironment (TGF-B, checkpoints, etc.).

[0095] For example, IL-12 and IL-18 play a major role in enhancing certain effector functions in T cells. IL-12 is known to activate certain NK cells and T lymphocytes, induce Th-1 type responses, and increase IFN-gamma secretion. Inducible expression of IL-12 may enhance the antitumor potential of CAR T cells against certain pathologies such as lymphoma, hepatocellular carcinoma, ovarian tumors, and B16 melanoma. IL-18 has also been used to improve the therapeutic potential of T cells. Initially identified as a potent inducer of IFN-gamma, IL-18 may contribute to T and NK cell activation as well as Th-1 cell polarization. For example, meso-targeted T cells can be supplied with a transgene encoding IL-18 to increase the secretion of IFN-gamma and eradicate cancer cells. For further discussion, see Tian, ​​2020, Gene modification strategies for next-generation CAR T cells against solid cancers, Journal of Hematology & Oncology, volume 13(5), which is incorporated by reference.

[0096] IL-7, IL-15, and IL-21 are useful for promoting the generation of stem cell-like memory T cell phenotypes. This phenotype can lead to increased proliferation and persistence of T cells in vivo. In some instances, a transgene encoding IL-2 is introduced into cells. Generating T cells with IL-2 can lead to T cells with improved ability to respond to conditions found in tumor environments. For example, providing IL-2 can promote the induction and production of proteins involved in nutrient sensing and uptake.

[0097] In some embodiments, the additional transgene introduced is an inhibitor of cytokine release syndrome. Cytokine release syndrome refers to a severe and potentially life-threatening side effect that often accompanies T cell therapy. Cytokine release syndrome manifests as a rapid (hyper)immune response resulting from excessive inflammatory cytokine release, including, for example, IFN-gamma and IL-6. Many cytokines involved in cytokine release syndrome are known to act through the JAK-STAT pathway. Thus, in some embodiments, the method of the invention includes generating T cells expressing an inhibitor of the JAK pathway to improve T cell proliferation, anti-tumor activity, and cytokine levels in vivo. For example, transgenes that inhibit the function of IL-6, JAK-STAT, or BTK can be provided. Furthermore, inhibitors can also be useful in inhibiting neurotoxicity. T cell-associated neurotoxicity is a syndrome that often leads to severe neurological disorders such as seizures and coma.

[0098] In other examples, the method includes introducing one or more transgenes into the HSCs that are used to generate T cells. In certain embodiments, the transgene is a checkpoint inhibitor, such as an immune checkpoint inhibitor. Immune checkpoints are regulators of certain aspects of the immune system. In normal physiological conditions, checkpoints allow the immune system to respond to host antigens that maintain healthy tissue. In cancer, these molecules promote the evasion of tumor cells. In some examples, the transgene may code for an antibody or antibody fragment, such as an anti-cathepsin antibody, a galectin-1 blocking antibody, and an anti-OX40 agonist antibody. The antibody may be secreted or expressed on the surface of the cell. For example, an antibody targeting PD1 or PDL1 may be secreted.

[0099] In certain embodiments, the introduced transgene expresses one or more inhibitors of transforming growth factor beta. Genetically modified cells face an unfavorable microenvironment that limits their efficacy. Regulating the environment can be useful to promote T cell proliferation, ability to survive and / or ability to kill cancer cells. One of the main inhibitory mechanisms within the tumor environment is transforming growth factor beta. Thus, some embodiments of the present invention include introducing a transgene that encodes an inhibitor of transforming growth factor beta. The inhibitor can be, for example, an antibody or a fragment thereof. The antibody or antibody fragment can be secreted from the T cell to interfere with the normal function of transforming growth factor beta.

[0100] Certain methods of the invention include generating multi-TCR T cells that target solid tumor types via markers of the tumor microenvironment. In certain embodiments, the methods of the invention include introducing a CAR after the introduction of a first TCR. In such methods, the CAR is introduced instead or in addition, depending on the requirements of the use of the cells. Thus, the invention includes a method of generating CAR T cells with single domain antibody (VHH)-based chimeric antigen receptors that can be used to recognize markers of the tumor microenvironment without the need for tumor-specific targets. The VHH-based CAR T cells according to the invention can target the tumor microenvironment via immune checkpoint receptors or via stromal and extracellular matrix markers and are effective against solid tumors in allogeneic immunodeficient animal models.

[0101] Thus, the method of the present invention is useful for generating CAR T cells that target tumors that may lack tumor-specific antigen expression. The variable regions of heavy chain-only antibodies (VHHs or nanobodies) are small, stable, camelid-derived, single-domain antibody fragments with affinities comparable to conventional short chain variable fragments (scFvs). VHHs are generally less immunogenic than scFvs, and due to their small size, they can access epitopes that are different from those recognized by scFvs. Thus, the VHHs provided by the present invention can function as suitable antigen recognition domains in CAR T cells. Unlike scFvs, VHHs do not require the additional folding and assembly steps associated with V-region pairing. VHHs allow for surface display without the need for extensive linker optimization or other types of reformatting. The ability to switch out different VHH-based recognition domains results in a highly modular platform that is accessible without the need to reformat each new conventional antibody into a scFv.

[0102] Many microenvironments involve the expression of inhibitory molecules such as PD-L1. Using VHHs, e.g., PD-L1-specific T cells, as recognition domains, multi-TCR, and TCR and CAR T cells generated by the methods of the present invention can target the tumor microenvironment. PD-L1 is widely expressed not only on tumor cells but also on infiltrating myeloid cells and lymphocytes. CAR / TCRs that recognize PD-L1 should alleviate immune inhibition while allowing T cell activation in the tumor microenvironment. Thus, T cells targeting PD-L1 can reprogram the tumor microenvironment, attenuate immune suppressive signals, and promote inflammation. For example, as discussed in Xie, 2019, Nanobody-based CAR T cells that target the tumor microenvironment inhibit the growth of solid tumors in immunocompetent mice, PNAS April 16, 2019 116(16)7624-7631, which is incorporated herein by reference.

[0103] According to aspects of the present disclosure, CD34+ stem cells are engineered to express a first TCR, one or more different TCR / CARs, and an additional transgene (e.g., a cytokine). In certain embodiments, one or more nucleic acids encoding the TCR(s), CAR(s), and / or additional transgenes are introduced using retroviral transduction. In certain embodiments, the first TCR and subsequent TCR / CARs are introduced at different times during the manufacturing process using retroviral transduction.

[0104] The combination of retroviral vectors that infect human cells in culture and suitable packaging is known in the art. In a preferred embodiment, a third generation lentiviral vector can be used to introduce the first TCR and / or the second TCR / CAR. The vector can be genetically engineered with a cDNA sequence that contains the sequence of an antibody or antibody fragment that targets a preferred antigen. As described, e.g., in Carpenito, 2008, Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains, PNAS, 106(9)3360-3365; Li, 2017, Redirecting T Cells to Glypican-3 with 4-1BB Zeta Chimeric Antigen Receptors Results in Th1 Polarization and Potent Antitumor Activity, Human Gene Therapy, 28(5):437-448; Adusumilli, 2014, Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity, Science Translational Medicine, 261(6):1-14; each of which is incorporated by reference.

[0105] Some embodiments of the present disclosure include introducing and expressing multiple transgenes into HSCs. To facilitate expression of multiple genes, it may be useful to isolate transgenes with 2A sequences, i.e., coding domains of 2A peptides, in nucleic acids. 2A self-cleaving peptides or 2A peptides are a class of 18-22 amino acid long peptides that can induce ribosomal skipping during protein translation. In a cell, when the coding domain of 2A peptide is inserted between two coding domains of two proteins (e.g., TCR and CAR), ribosomal skipping will translate the peptide into two independently folded proteins.

[0106] The method of the present invention is useful for transforming genetically modified HSCs into T cells for clinical application. The transformation method generally involves, in part, differentiation of HSCs into T cells by the introduction of a first TCR. Cell differentiation is the process by which cells change from one cell type to another. Usually, cells change into a more specialized type. Differentiation of HSCs into T cells can involve multiple differentiation steps. As a first step, CD34+ cells can be differentiated into CD4 CD8 double negative T cells. Generation of double negative T cells can be achieved by culturing CD34+ cells in the presence of a cell factor cocktail including hematopoietic cytokines. The cocktail can include SCF (e.g., hSCF), Flt3L (e.g., hFlt3L), at least one cytokine, and bFGF for hematopoietic specification. The cytokine can be a Th1 cytokine, including, but not limited to, IL-3, IL-15, IL-7, IL-12, and IL-21. Cells can be immunophenotyped by FACS for expression of CD34, CD31, CD43, CD45, CD41a, ckit, Notch1, and IL7Rα.

[0107] The double negative T cells may be further differentiated through an antigen-independent maturation process to generate functional inactivated T cells. This process may include culturing the double negative T cells in lymphoid progenitor cell growth medium. The medium may include, for example, feeder cells, SCF, Flt3L, and at least one cytokine. The cytokine may be a Th1 cytokine, including, but not limited to, IL-3, IL-15, IL-7, IL-12, and IL-21. In some embodiments, the cytokine may enhance the survival and / or functional capacity of the cells.

[0108] Cell products comprising T cells, including multi-TCR T cells that have not undergone an activation and / or expansion step, can be delivered systemically or directly to a subject for the treatment of a neoplasm, a pathogen infection, or an infectious disease. In one embodiment, the multi-TCR T cells of the invention can be directly injected into an organ of interest (e.g., an organ in which a neoplasm has arisen). Alternatively, the multi-TCR T cells and compositions comprising the cells can be delivered indirectly to an organ of interest, for example, by administration into the circulatory system (e.g., tumor vasculature). In certain aspects, activation and expansion of the T cells occurs in vivo after introduction into the subject.

[0109] The T cells of the invention and compositions comprising the cells can be administered in any physiologically acceptable vehicle, usually intravascularly, but also into bone or other convenient sites where the cells can find a suitable site for regeneration and differentiation (e.g., the thymus). Typically, at least 100,000 cells, and sometimes more than 10,000,000,000 cells, are administered.

[0110] The method of the present invention provides compositions of cells that can be combined with pharmaceutical compositions for administration in allogeneic cell therapy. When administering the therapeutic compositions of the present invention (e.g., pharmaceutical compositions comprising multi-TCR T cells derived from HSCs), the compositions are generally formulated in a unit dose injectable form (solution, suspension, emulsion). The compositions can be provided at a therapeutically effective concentration. A therapeutically effective concentration is an amount sufficient to effect a beneficial or desired clinical outcome by treatment. An effective amount can be administered to a subject in one or more doses. In terms of treatment, an effective amount is an amount sufficient to alleviate, ameliorate, stabilize, reverse or delay the progression of a disease, or otherwise reduce the pathological consequences of a disease. An effective amount is generally determined by a physician on a case-by-case basis and is within the skill of one of ordinary skill in the art. In determining the appropriate dosage to achieve an effective amount, several factors are typically considered. These factors include the age, sex, and weight of the subject, the condition being treated, the severity of the condition, and the form and effective concentration of the antigen-binding fragment to be administered.

[0111] In adoptive immunotherapy using the antigen-specific multi-TCR T cells of the present invention, cell doses ranging from 10,000,000 to 10,000,000,000 can be infused. Upon administration of the multi-TCR T cells to a subject, the T cells may undergo an antigen-dependent activation process.

[0112] The present disclosure provides methods for producing multi-TCR T cells for cell therapy and / or research. In certain embodiments, the methods provide for economical production of multi-TCR T cells by reducing the time of ex vivo cell culture. In certain related embodiments, the methods of the present invention provide for production of multi-TCR T cells with enhanced cytotoxic potency. Long-term cell culture has traditionally been accompanied by transcriptional and phenotypic changes in certain cell types. Although the transcriptional and phenotypic changes of T cells during culture are not well defined, the present disclosure recognizes that unintended changes in cells during long-term culture may explain the observed reduction in therapeutic efficacy and production batch variability observed with allogeneic cells. For example, long-term cell culture of T cells may cause increased levels of exhaustion markers that reflect loss of effector function. For example, long-term culture may be accompanied by increased expression of PD1, LAG3, CD244, CD160. For further discussion, see Wherry, 2016, Molecular and cellular insights into T cell exhaustion, Nat Rev Immunol, 15(8):486-499, which is incorporated by reference. By shortening ex vivo production, the methods of the invention are useful for consistent generation of therapeutically effective T cells.

[0113] Thus, in one aspect, the disclosure provides a method of generating T cells. The method includes performing a process involving in vitro differentiation and maturation of hematopoietic stem cells (HSCs) into multi-TCR T cells, with the proviso that the process does not include an in vitro step of activation and / or expansion of the multi-TCR T cells, either before or after the introduction of a second TCR. In certain embodiments, activation and / or expansion of the multi-TCR T cells occurs in vivo after introduction into the subject. In certain embodiments, activation and / or expansion occurs both in vivo and in vitro. In certain embodiments, the method of generating multi-TCR T cells includes only a single in vitro activation and / or expansion step. Advantageously, by omitting the multiple in vitro activation and / or T cell expansion steps in conventional methods that generate only single-TCR T cells, the method of the present invention can generate multi-TCR T cells in a shorter time and can generate T cells with enhanced therapeutic potency.

[0114] The methods of the invention are useful for providing safe and effective allogeneic therapy. In some examples, the methods may include characterizing the cell product at one or more time points during manufacturing to ensure product quality. In some embodiments, the methods of the invention include analyzing T cells after introduction of the first and / or second TCR to identify one or more proteins expressed by the T cells. The one or more proteins may include one or more of CCR7, CD62L, or CD45RA. The proteins may include markers associated with naive stem cells. The analysis preferably includes high-throughput methods of analyzing cell surface proteins, such as fluorescent signal-based methods on individual cells in bulk, such as FACS. In certain methods of the invention, multiple analysis steps are used to ensure the introduction of the first TCR and then the second TCR.

[0115] The ability to treat on demand is one advantage of allogeneic cell therapy. As the method may include the production of cells prior to clinical application, some preferred methods may include cryopreserving T cells. This may include cryopreserving multi-TCR T cells. In a preferred embodiment, the method of the present invention includes generating T cells from HSCs after the introduction of a first TCR. The resulting TCR is cryopreserved until needed. When needed, a second TCR specific for a particular patient's antigen is introduced into the stored TCR to generate multi-TCR. This dramatically shortens the lead time required to generate patient-specific multi-TCR T cells. Cryopreserving T cells is useful for safe and effective storage of cells until they are needed by the patient. Cryopreservation is also useful for transporting the cell product to a clinical facility where it can be administered to the patient. In some preferred embodiments, double positive T cells (e.g., naive T cells) are cryopreserved without an in vitro activation step. In certain embodiments, a second TCR is introduced into the stored naive T cells. Following introduction of the second TCR, the cells may undergo one or more proliferation, activation, maturation, and / or storage steps.

[0116] Over the past decade, immunotherapy has become a new generation of cancer treatment. In particular, cell-based cell therapy has shown great promise. A prominent example is genetically modified adoptive T cell therapy, which has been shown to effectively target certain blood cancers and have remarkable efficacy. However, most current therapeutic protocols consist of autologous adoptive cell transfer, in which immune cells taken from a patient are processed and used to treat this single patient. Such approaches are costly, laborious to manufacture, and difficult to widely deliver to all patients who need them. There is a great demand for allogeneic immune cell products by the methods described herein, as they can be manufactured on a large scale and easily distributed to treat a larger number of patients.

[0117] Some embodiments relate to genetically modified iNKT cells or populations of genetically modified iNKT cells with multiple TCRs. In at least some cases, the genetically modified iNKT cells comprise at least one genetically modified T cell receptor. In certain aspects, the cells comprise two or more genetically modified TCRs. Alternatively, or in addition, the cells comprise an endogenous TCR and one or more genetically modified TCRs. Any embodiment discussed in relation to cells can be applied to such populations of cells. In certain embodiments, the genetically modified iNKT cells comprise a nucleic acid comprising one, two, and / or three of the following: i) all or a portion of an invariant alpha T cell receptor coding sequence; ii) all or a portion of an invariant beta T cell receptor coding sequence; or iii) an additional transgene. In further embodiments, there are genetically modified iNKT cells comprising a nucleic acid having a sequence encoding the following: i) all or a portion of an invariant alpha TCR; ii) all or a portion of an invariant beta TCR; and / or iii) an additional transgene. In certain methods of the invention, one or more additional TCRs are introduced into these iNKT cells.

[0118] In certain aspects, the genetically modified iNKT cells are genetically modified to express increased levels of NK activating receptors, decreased levels of NK inhibitory receptors, and / or increased levels of cytotoxic molecules. In some embodiments, the NK activating receptors include NKG2D and / or DNAM-1. In some embodiments, the cytotoxic molecules include perforin and / or granzyme B. In some embodiments, the inhibitory receptors include KIR. The increase or decrease can be relative to the levels of the same markers in non-genetically modified iNKT cells isolated from healthy individuals. Further aspects relate to a population of genetically modified iNKT cells, the population of cells having increased levels of NK activating receptors, decreased levels of NK inhibitory receptors, and / or increased levels of cytotoxic molecules.

[0119] In some embodiments, the genetically modified iNKT cells comprise a nucleic acid under the control of a heterologous promoter, meaning that the promoter is not the same genomic promoter that controls transcription of the nucleic acid. It is contemplated that the genetically modified iNKT cells comprise an exogenous nucleic acid comprising one or more coding sequences, some or all of which are under the control of a heterologous promoter in many embodiments described herein.

[0120] In certain embodiments, there are genetically modified invariant natural killer T (iNKT) cells expressing at least one invariant natural killer T cell receptor (iNKT TCR) and a second introduced TCR, and a suicide gene, where the at least one iNKT TCR is expressed from an exogenous nucleic acid and / or from an endogenous invariant TCR gene under the transcriptional control of a recombinant modified promoter region. iNKT TCR refers to a "TCR that recognizes lipid antigens presented by CD1d molecules." iNKT TCRs can include alpha-TCRs, beta-TCRs, or both. In some instances, the TCR utilized can belong to a broader group of "invariant TCRs," such as MAIT cell TCRs, GEM cell TCRs, or gamma / delta TCRs, resulting in HSC genetically modified MAIT cells, GEM cells, or gamma / delta T cells, respectively.

[0121] In certain embodiments, the suicide gene is enzyme-based, meaning that the gene product of the suicide gene is an enzyme and the suicide function depends on the enzymatic activity. One or more suicide genes can be utilized in a single cell or a clonal population. In some embodiments, the suicide gene encodes herpes simplex virus thymidine kinase (HSV-TK), purine nucleoside phosphorylase (PNP), cytosine deaminase (CD), carboxypeptidase G2, cytochrome P450, linamarase, beta-lactamase, nitroreductase (NTR), carboxypeptidase A, or inducible caspase 9. Methods in the art for using suicide genes can be used, such as those described in U.S. Patent No. 8,628,767, U.S. Patent Application Publication No. 20140369979, U.S. Patent No. 20140242033, and U.S. Patent No. 20040014191, all of which are incorporated by reference in their entirety.

[0122] In further embodiments, the TK gene is a viral TK gene, i.e., a TK gene derived from a virus. In certain embodiments, the TK gene is a herpes simplex virus TK gene. In some embodiments, the suicide gene product is activated by a substrate. Thymidine kinase is a suicide gene product that is activated by ganciclovir, penciclovir, or derivatives thereof. In certain embodiments, the substrate that activates the suicide gene product is labeled for detection. In some instances, the substrate may be labeled for imaging. In some embodiments, the suicide gene product may be encoded by the same or different nucleic acid molecules that encode one or both of TCR-alpha or TCR-beta. In certain embodiments, the suicide gene is sr39TK or inducible caspase 9. In another embodiment, the cells do not express an exogenous suicide gene. In some embodiments, the genetically modified iNKT cells specifically bind alpha-galactosylceramide (a-GC).

[0123] In further embodiments, the multi-TCR T cells generated by the methods of the invention comprise T cells with no or reduced surface expression of at least one HLA-I or HLA-II molecule. In some embodiments, the absence of surface expression of HLA-I and / or HLA-P molecules is achieved by disrupting genes encoding individual HLA-I / II molecules, or by disrupting genes encoding B2M (beta 2 microglobulin), a common component of all HLA-I complex molecules, or by disrupting genes encoding CIITA (class II major histocompatibility complex transactivator), a key transcription factor that controls the expression of all HLA-II genes. In certain embodiments, the cells have no surface expression of one or more HLA-I and / or HLA-II molecules, or the expression levels of such molecules are reduced by (at least) 50, 60, 70, 80, 90, 100% (or any range derivable therein). In some embodiments, the iNKT cells have been engineered by gene editing such that HLA-I or HLA-II are not expressed in the cells.

[0124] In some embodiments, the iNKT cells contain one or more recombinant vectors or nucleic acid sequences from one or more recombinant vectors introduced into the cells. In certain aspects, the iNKT cells contain two or more recombinant vectors introduced at different times during the manufacturing process. In certain embodiments, the recombinant vector is or was a viral vector. In further embodiments, the viral vector is or was a lentivirus, retrovirus, adeno-associated virus (AAV), herpes virus, or adenovirus. It is understood that the nucleic acid of certain viral vectors is integrated into the host genome sequence.

[0125] A "vector" or "construct" (sometimes called a gene delivery or gene transfer "vehicle") refers to a polymer, molecular complex, or viral particle containing a polynucleotide that is delivered to a host cell either in vitro or in vivo. The polynucleotide may be a linear or circular molecule. A "plasmid," a common type of vector, is an extrachromosomal DNA molecule separate from chromosomal DNA that can replicate independently of the chromosomal DNA. In certain cases, the plasmid is circular and double stranded.

[0126] A "gene," "transgene," "polynucleotide," "coding region," "sequence," "segment," "fragment," or "transgene" that "encodes" a particular protein is a nucleic acid molecule that, when placed under the control of appropriate regulatory sequences, is transcribed and, optionally, translated into a gene product (e.g., a polypeptide), in vitro or in vivo. The coding region may be present in the form of either cDNA, genomic DNA, or RNA. If present in the form of DNA, the nucleic acid molecule may be single-stranded (i.e., the sense strand) or double-stranded. The boundaries of a coding region are determined by a start codon at the 5' (amino) terminus and a translation stop codon at the 3' (carboxy) terminus. A gene may include, but is not limited to, cDNA from prokaryotic or eukaryotic mRNA, genomic DNA sequences from prokaryotic or eukaryotic DNA, and synthetic DNA sequences. A transcription termination sequence is usually located 3' to the gene sequence.

[0127] The term "cell" as used herein is used in the broadest sense in the art and refers to a structural unit of tissue in a multicellular organism, surrounded by a membrane structure that isolates it from the outside, capable of self-replication, and having genetic information and a mechanism for expressing said genetic information. A cell as used herein may be a naturally occurring cell or an artificially modified cell (e.g., a fused cell, a genetically modified cell, etc.).

[0128] iNKT cells are a small population of alpha-beta T lymphocytes that are highly conserved from mice to humans. iNKT cells have been suggested to play important roles in the control of many diseases, including cancer, infectious diseases, allergies, and autoimmunity. Upon stimulation, iNKT cells rapidly release large amounts of effector cytokines, such as IFN-gamma and IL-4, both as a cell population and at the single-cell level. These cytokines then activate various immune effector cells, such as natural killer cells and dendritic cells (DCs) of the innate immune system, as well as CD4 helper T cells and CD8 cytotoxic conventional alpha-beta T cells of the adaptive immune system via activated DCs. The unique activation mechanism of iNKT cells allows them to attack multiple diseases independently of antigen and MHC restriction, making them an attractive and versatile therapeutic agent.

[0129] To date, a series of iNKT cell-based clinical trials have been conducted, mainly targeting cancer. Recent clinical trials have reported the promotion of antitumor immunity in patients with head and neck squamous cell carcinoma, proving the potential of iNKT cell-based immunotherapy. However, most clinical trials to date have been based on direct activation or ex vivo expansion of endogenous iNKT cells, which have only provided short-term, limited clinical benefit to a small number of patients and have not produced satisfactory results. The low and highly variable presence of human iNKT cells (approximately 0.01-1% in the blood) and their rapid depletion after activation are thought to be major obstacles to the success of these trials.

[0130] iNKT cells are genetically modified from induced pluripotent stem (iPS) cells. See U.S. Patent No. 8,945,922, which is incorporated by reference. iPS cells are generated by introducing exogenous nuclear reprogramming factors, such as Oct4, Sox2, Klf4, and c-Myc, into somatic cells. Unfortunately, the transcription levels of exogenous nuclear reprogramming factors decline as cells transition to a pluripotent state, which may reduce the efficiency of producing stable iPS cell lines. Furthermore, because Oct4, Sox2, Klf4, and c-Myc are oncogenes that lead to carcinogenesis, transcription of exogenous nuclear reprogramming factors may be resumed in iPS cells, leading to neoplastic development from cells derived from iPS cells.

[0131] The methods of the present invention can be used to generate iNKT cells, for example, as discussed in U.S. Patent Application Publication No. 20170283481(A1) and International Patent Application No. 2019241400, each of which is incorporated by reference.

[0132] By way of example, in some embodiments, the methods of the invention generate iNKT cells, including double-negative iNKT cells, that include one or more iNKT TCR nucleic acid sequences obtained from a subset of iNKT cells, such as the CD4 / DN / CD8 subset or a subset that produces Th1, Th2, or Th17 cytokines. In some embodiments, the iNKT TCR nucleic acid sequences are obtained from iNKT cells of a donor who was or is suffering from cancer, e.g., melanoma, renal cancer, lung cancer, prostate cancer, breast cancer, lymphoma, leukemia, hematological malignancies, and the like. In some embodiments, the iNKT TCR nucleic acid molecule has a TCR alpha sequence from one iNKT cell and a TCR beta sequence from a different iNKT cell. In some embodiments, the iNKT cell from which the TCR alpha sequence is obtained and the iNKT cell from which the TCR beta sequence is obtained are obtained from the same donor. In some embodiments, the donor of the iNKT cell from which the TCR alpha sequence is obtained is different from the donor of the iNKT cell from which the TCR beta sequence is obtained. In some embodiments, the TCR alpha and / or TCR beta sequences are codon-optimized for expression. In some embodiments, the TCR alpha and / or TCR beta sequences are modified to encode a polypeptide having one or more amino acid substitutions, deletions, and / or truncations compared to the polypeptide encoded by the unmodified sequence. In some embodiments, the iNKT TCR nucleic acid molecule encodes a T cell receptor that recognizes alpha-galactosylceramide (alpha-GalCer) presented on CD1d. In some embodiments, the iNKT TCR nucleic acid molecule is contained in an expression vector. In some embodiments, the expression vector is a lentiviral expression vector. In some embodiments, the expression vector is a MIG vector with the iNKT TCR nucleic acid molecule replacing the IRES-EGFP segment of the MIG vector. In some embodiments, the expression vector is phiNKT-EGFP.

[0133] In some embodiments, the nucleic acid may comprise a nucleic acid sequence encoding an α-TCR and / or a β-TCR as discussed herein. In certain embodiments, one nucleic acid encodes both an α-TCR and a β-TCR. In further embodiments, the nucleic acid further comprises a nucleic acid sequence encoding a suicide gene product. In some embodiments, the nucleic acid molecule introduced into the selected CD34+ cells encodes an α-TCR, a β-TCR, and a suicide gene product. In other embodiments, the method also comprises introducing a nucleic acid encoding a suicide gene product into the selected CD34+ cells, where a nucleic acid molecule different from the nucleic acid encoding at least one of the TCR genes encodes the suicide gene product.

[0134] Methods for preparing, generating, producing, and using genetically modified iNKT cells and iNKT cell populations are provided. The method may, in embodiments, include one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, or more of the following steps: obtaining hematopoietic cells; obtaining hematopoietic progenitor cells; obtaining progenitor cells capable of becoming one or more hematopoietic cells; obtaining progenitor cells capable of becoming iNKT cells; selecting cells from a population of mixed cells using one or more cell surface markers; selecting CD34+ cells from the cell population; isolating CD34+ cells from the cell population; separating CD34+ cells from CD34- cells; selecting cells based on a cell surface marker other than or in addition to CD34; introducing into the cells one or more nucleic acids encoding an iNKT T cell receptor (TCR); infecting the cells with a viral vector encoding an iNKT T cell receptor (TCR); transfecting into the cells one or more nucleic acids encoding an iNKT T cell receptor (TCR); transfecting into the cells an expression construct encoding an iNKT T cell receptor (TCR); Integrating an exogenous nucleic acid encoding a T cell receptor (TCR) into the genome of a cell;introducing one or more nucleic acids encoding a suicide gene product into a cell;infecting a cell with a viral vector encoding a suicide gene product;transfecting a cell with one or more nucleic acids encoding a suicide gene product;transfecting a cell with an expression construct encoding a suicide gene product;integrating an exogenous nucleic acid encoding a suicide gene product into the genome of a cell;introducing one or more nucleic acids encoding one or more polypeptides and / or nucleic acid molecules into a cell for gene editing;infecting a cell with a viral vector encoding one or more polypeptides and / or nucleic acid molecules for gene editing;transfecting a cell with one or more nucleic acids encoding one or more polypeptides and / or nucleic acid molecules for gene editing;transfecting a cell with an expression construct encoding one or more polypeptides and / or nucleic acid molecules for gene editing;Incorporating exogenous nucleic acids and / or nucleic acid molecules encoding one or more polypeptides for gene editing; editing the genome of a cell; editing the promoter region of a cell; editing the promoter and / or enhancer region of an iNKT TCR gene; suppressing expression of one or more genes; suppressing expression of one or more HLA-I / II genes in isolated human CD34+ cells; transfecting one or more nucleic acids into a cell for gene editing; culturing the isolated or selected cells; expanding the isolated or selected cells; culturing cells selected for one or more cell surface markers; culturing isolated CD34+ cells expressing iNKT TCR; expanding the isolated CD34+ cells; culturing cells under conditions to generate or expand iNKT cells; culturing cells in an artificial thymic organoid (ATO) system to generate iNKT cells; culturing cells in serum-free medium; culturing cells in an ATO system, the ATO system comprising 3D cell aggregates comprising a selected population of stromal cells expressing a Notch ligand and serum-free medium. It is specifically contemplated that in one embodiment, one or more steps may be omitted.

[0135] The cells that can be used to generate genetically modified iNKT cells are hematopoietic progenitor stem cells. The cells may be obtained from peripheral blood mononuclear cells (PBMCs), bone marrow cells, fetal liver cells, embryonic stem cells, umbilical cord blood cells, or combinations thereof. The present disclosure encompasses "HSC-iNKT cells," invariant natural killer T (iNKT) cells genetically modified from hematopoietic stem cells (HSCs) and / or hematopoietic progenitor cells (HPCs), and methods of generating and using them. As used herein, "HSCs" is used to refer to HSCs, HPCs, or both HSCs and HPCs. "Hematopoietic stem and progenitor cells" or "hematopoietic progenitor cells" refer to cells that are committed to the hematopoietic lineage but capable of further hematopoietic differentiation, including hematopoietic stem cells, multipotent hematopoietic stem cells (hematopoietic blasts), myeloid progenitor cells, megakaryocyte progenitor cells, erythroid progenitor cells, and lymphoid progenitor cells. "Hematopoietic stem cells (HSCs)" are pluripotent stem cells that give rise to all blood cell types, including myeloid (monocytes and macrophages, neutrophils, basophils, eosinophils, erythrocytes, megakaryocytes / platelets, dendritic cells) and lymphoid (T cells, B cells, NK cells). In this disclosure, HSCs refer to both "hematopoietic stem and progenitor cells" and "hematopoietic progenitor cells." Hematopoietic stem cells and hematopoietic progenitor cells may or may not express CD34. Hematopoietic stem cells may co-express CD133, be negative for CD38 expression, positive for CD90, negative for CD45RA, negative for lineage markers, or combinations thereof. Hematopoietic progenitor / progenitor cells include CD34(+) / CD38(+) cells and CD34(+) / CD45RA(+) / lin(-)CD10+ (common lymphoid progenitor cells), CD34(+)CD45RA(+)lin(-)CD10(-)CD62L(hi) (lymphoid-stimulated multipotent progenitor cells), CD34(+)CD45RA(+)lin(-)CD10(-)CD123+ (granulocyte-monocyte progenitor cells), CD34(+)CD45RA(-)lin(-)CD10(-)CD123+ (common myeloid progenitor cells), or CD34(+)CD45RA(-)lin(-)CD10(-)CD123- (megakaryocyte-erythroid progenitor cells).

[0136] Certain methods include culturing the selected CD34+ cells in a medium prior to introducing one or more nucleic acids into the cells. Culturing the cells can include incubating the selected CD34+ cells with a medium comprising one or more growth factors. In some embodiments, the one or more growth factors comprise c-kit ligand, flt-3 ligand, and / or human thrombopoietin (TPO). In further embodiments, the medium comprises c-kit ligand, flt-3 ligand, and TPO. In some embodiments, the concentration of the one or more growth factors is from about 5 ng / mL to about 500 ng / mL, either for each growth factor or for the sum of any and all of these particular growth factors. The concentration of a single growth factor or combination of growth factors in the medium is about, at least about, or at most about 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 105, 110, 115, 120, 125, 130, 135, 140, 145, 150, 155, 160, 165, 170, 175, 180, 185, 190, 195, 200, 205, 210, 215, 220, 225, 230, 235, 240, 245, 250, 255, 260, 265, 270, 275, 280, 285, 290, 300, 305, 310, 320, 330, 340, 350, 360, 370, 385, 390, 400, 410, 420, 430, 440, 450, 460, 470, 480, 490, 500, 510, 520, 530, 540, 550, 560, 570, 580, 590, 600, 610, 620, 630, 640, 650, 660, 670, 680, 690, 700, 710, The concentration may be greater than or equal to 40, 245, 250, 255, 260, 265, 270, 275, 280, 285, 290, 295, 300, 305, 310, 315, 320, 325, 330, 335, 340, 345, 350, 355, 360, 365, 370, 375, 380, 385, 390, 395, 400, 410, 420, 425, 430, 440, 441, 450, 460, 470, 475, 480, 490, 500 (or any derivable range) ng / mL or mg / mL.

[0137] In some embodiments, the cells are cultured in cell-free medium. In certain embodiments, the serum-free medium further comprises exogenously added ascorbic acid. In certain embodiments, the method comprises adding ascorbic acid to the medium. In further embodiments, the serum-free medium further comprises one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, or all sixteen (or any range derivable therein) of the following exogenously added components: FLT3 ligand (FLT3L), interleukin 7 (IL-7), stem cell factor (SCF), thrombopoietin (TPO), stem cell factor (SCF), IL-2, IL-4, IL-6, IL-15, IL-21, TNF-alpha, TGF-beta, interferon-gamma, interferon-lambda, TSLP, thymopentin, pleiotrophin, or midkine. In further embodiments, the serum-free medium comprises one or more vitamins. In some cases, the serum-free medium comprises one, two, three, four, five, six, seven, eight, nine, ten, eleven, or twelve of the following vitamins (or any range derivable therein): biotin, DL alpha tocopherol acetate, DL alpha-tocopherol, vitamin A, choline chloride, calcium pantothenate, pantothenic acid, folic acid nicotinamide, pyridoxine, riboflavin, thiamine, inositol, vitamin B12, or a salt thereof. In certain embodiments, the medium comprises, or at least comprises, biotin, DL alpha tocopherol acetate, DL alpha-tocopherol, vitamin A, or a combination or salt thereof. In further embodiments, the serum-free medium comprises one or more proteins. In some embodiments, the serum-free medium comprises one, two, three, four, five, six, or more (or any range derivable therein) of the following proteins: albumin or bovine serum albumin (BSA), a fraction of BSA, catalase, insulin, transferrin, superoxide dismutase, or a combination thereof.In other embodiments, the serum-free medium comprises one, two, three, four, five, six, seven, eight, nine, ten, or eleven of the following compounds: corticosterone, D-galactose, ethanolamine, glutathione, L-carnitine, linoleic acid, linolenic acid, progesterone, putrescine, sodium selenite, or triiodo-I-thyronine, or a combination thereof. In further embodiments, the serum-free medium comprises B-27 supplement, xeno-free B-27 supplement, GS21™ supplement, or a combination thereof. In further embodiments, the serum-free medium comprises, or further comprises, amino acids, monosaccharides, and / or inorganic ions. In some embodiments, the serum-free medium comprises one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, or thirteen of the following amino acids: arginine, cysteine, isoleucine, leucine, lysine, methionine, glutamine, phenylalanine, threonine, tryptophan, histidine, tyrosine, or valine, or a combination thereof. In other embodiments, the serum-free medium comprises one, two, three, four, five, or six of the following inorganic ions: sodium, potassium, calcium, magnesium, nitrogen, or phosphorus, or a combination or salt thereof. In further embodiments, the serum-free medium comprises one, two, three, four, five, six, or seven of the following elements: molybdenum, vanadium, iron, zinc, selenium, copper, or manganese, or a combination thereof.

[0138] In some methods, the cells are cultured in an artificial thymic organoid (ATO) system. The ATO system comprises a three-dimensional (3D) cell aggregate, which is an aggregate of cells. In certain embodiments, the 3D cell aggregate comprises a selected population of stromal cells expressing a Notch ligand. In some embodiments, the 3D cell aggregate is made by mixing CD34+ transduced cells with a selected population of stromal cells on a physical matrix or scaffold. In further embodiments, the method comprises centrifuging the CD34+ transduced cells and stromal cells to form a cell pellet disposed on the physical matrix or scaffold. In certain embodiments, the stromal cells express a Notch ligand that is intact, partial, or modified DLL1, DLL4, JAG1, JAG2, or a combination thereof. In further embodiments, the Notch ligand is a human Notch ligand. In other embodiments, the Notch ligand is human DLL1.

[0139] The cells may be used immediately or may be stored for future use. In certain embodiments, the cells used to generate iNKT cells are frozen, although the generated iNKT cells may be frozen in some embodiments. In certain aspects, the cells are in a solution comprising dextrose, one or more electrolytes, albumin, dextran, and DMSO. In other embodiments, the cells are in a sterile, non-pyrogenic, and isotonic solution. In some embodiments, the genetically modified iNKT cells are derived from hematopoietic stem cells. In some embodiments, the genetically modified iNKT cells are derived from G-CSF mobilized CD34+ cells. In some embodiments, the cells are derived from cells of a human patient without cancer. In some embodiments, the cells do not express an endogenous TCR.

[0140] The genetically modified iNKT cells can be used to treat patients. In some embodiments, the method includes introducing one or more additional nucleic acids into the cell population, which may or may not have been previously frozen and thawed. This use provides one of the advantages of producing ready-made iNKT cells. In certain embodiments, the one or more additional nucleic acids code for one or more therapeutic gene products. Examples of therapeutic gene products include at least: 1. antigen recognition molecules such as CAR (chimeric antigen receptor) and / or TCR (T cell receptor); 2. costimulatory molecules such as CD28, 4-1BB, 4-1BBL, CD40, CD40L, ICOS; and / or 3. cytokines such as IL-lcc, IL-Ib, IL-2, IL-4, IL-6, IL-7, IL-9, IL-15, IL-12, IL-17, IL-21, IL-23, IFN-g, TNF-a, TGF-b, G-CSF, GM-CSF; 4. transcription factors such as T-bet, GATA-3, RORyt, FOXP3, Bcl-6. Therapeutic antibodies are included as chimeric antigen receptors, single chain antibodies, monobodies, humanized antibodies, bispecific antibodies, single chain FV antibodies or combinations thereof.

[0141] In some embodiments, the present invention provides kits comprising one or more genetically modified cells or compositions according to the present invention packaged with a drug delivery device, e.g., a syringe, for delivering the genetically modified cells or compositions to a subject. In some embodiments, the present invention provides kits comprising one or more genetically modified cells or compositions according to the present invention packaged with one or more reagents for culturing and / or storing the genetically modified cells. In some embodiments, the present invention provides kits comprising one or more genetically modified cells or compositions according to the present invention packaged with one or more agents for activating cells, e.g., iNKT cells comprising a CAR and at least one additional transgene. In some embodiments, the present invention provides kits comprising one or more genetically modified cells or compositions according to the present invention packaged with OP9-DL1 stromal cells and / or MS5-DL4 stromal cells. In some embodiments, the present invention provides kits comprising one or more genetically modified cells or compositions according to the present invention packaged with antigen presenting cells or CD1d-expressing artificial antigen presenting cells.

[0142] The methods of the invention provide methods for producing genetically modified cells for treating any number of conditions and / or diseases. In some embodiments, the invention provides methods for treating a subject, comprising administering to the subject one or more genetically modified cells according to the invention, one or more genetically modified cells made according to the methods of the invention, one or more compositions according to the invention. In some embodiments, the subject is an animal, such as a mouse or a laboratory animal. In some embodiments, the subject is a human. In some embodiments, the subject has cancer, a bacterial infection, a viral infection, an allergy, or an autoimmune disease. In some embodiments, the cancer is melanoma, kidney cancer, lung cancer, prostate cancer, breast cancer, lymphoma, leukemia, or a hematological malignancy. In some embodiments, the subject has tuberculosis, HIV, or hepatitis. In some embodiments, the subject has asthma or eczema. In some embodiments, the subject has type I diabetes, multiple sclerosis, or arthritis. In some embodiments, the subject is administered a therapeutically effective amount of one or more genetically modified cells. In some embodiments, a therapeutically effective amount of the one or more genetically modified cells is about 10×10 per kg of body weight of the subject being treated. 7 ~About 10×10 9 In some embodiments, the method further comprises administering an agent that activates iNKT cells, such as α-GalCer or a salt or ester thereof, α-GalCer-presenting dendritic cells, or artificial APCs, before, during, and / or after administration of the one or more genetically modified cells.

[0143] The term "chimeric antigen receptor" or "CAR" refers to a genetically engineered receptor that fuses any specificity to an immune effector cell. These receptors are used to fuse the specificity of a monoclonal antibody to T cells, the transfer of the coding sequence being facilitated by retroviral or lentiviral vectors. The receptors are called chimeric because they are composed of parts from different sources. The most common form of these molecules is the fusion of a single chain variable fragment (scFv) from a monoclonal antibody with the CD3-zeta transmembrane and endodomains, the CD28 or 41BB intracellular domains, or a combination thereof. Such molecules transmit a signal in response to target recognition by the scFv. An example of such a construct is 14g2a-Zeta, a fusion with an scFv from hybridoma 14g2a (recognizing disialoganglioside GD2). When T cells express this molecule (achieved, for example, by oncoretroviral vector transduction), they recognize and kill target cells expressing GD2 (e.g., neuroblastoma cells). To target malignant B cells, researchers have redirected the specificity of T cells using chimeric immune receptors specific for the B-lineage molecule CD19. The variable regions of immunoglobulin heavy and light chains are fused by a flexible linker to form an scFv. This scFv is preceded by a signal peptide that directs the nascent protein to the endoplasmic reticulum for subsequent surface expression (which is cleaved). A flexible spacer allows the scFv to orient in various directions to allow antigen binding. The transmembrane domain is a typical hydrophobic alpha helix, usually derived from the original molecule in a signaling endodomain, and protrudes into the cell to transmit the desired signal.

[0144] In a particular embodiment, the present invention provides a method for generating CAR T cells from HSCs. The method can include introducing a first TCR into HSCs to generate T cells, preferably gamma delta T cells or iNKT cells. Then, introduce a CAR or a second TCR and a CAR into T cells. As a result, TCR and CAR, or multi-TCR and CAR cells are generated.

[0145] Preferably, the CAR is directed against a specific tumor antigen. Examples of tumor antigens to which the CAR can be directed include, for example, the EGFR family, which includes at least 5T4, 8H9, anbb integrin, BCMA, B7-H3, B7-H6, CAIX, CA9, CD19, CD20, CD22, CD30, CD33, CD38, CD44, CD44v6, CD44v7 / 8, CD70, CD123, CD138, CD171, CEA, CSPG4, EGFR, ErbB2 (HER2), EGFRvIII, EGP2, EGP40, ERBB3, ERBB4, ErbB3 / 4, EPCAM, EphA2, EpCAM, Folate receptor-a, FAP, FBP, fetal AchR, FRcc, GD2, G250 / CAIX, GD3, glypican-3 (GPC3), Her2, IL-l3Rcx2, lambda, Lewis-Y, kappa, KDR, MAGE, MCSP, mesothelin, Mucl, Mucl6, NCAM, NKG2D ligand, NY-ESO-1, PRAME, PSC1, PSCA, PSMA, ROR1, SP17, survivin, TAG72, TEM, carcinoembryonic antigen, HMW-MAA, AFP, CA-125, ETA, tyrosinase, MAGE, laminin receptor, HPV Examples of the CAR include E6, E7, BING-4, calcium activated chloride channel 2, Cyclin-Bl, 9D7, EphA3, telomerase, SAP-1, BAGE family, CAGE family, GAGE ​​family, MAGE family, SAGE family, XAGE family, NY-ESO-1 / LAGE-1, PAME, SSX-2, Melan-A / MART-1, GP100 / pmell7, TRP-1 / -2, P. polypeptide, MC1R, prostate specific antigen, b-catenin, BRCA1 / 2, CML66, fibronectin, MART-2, TGF^RII, or VEGF receptor (e.g., VEGFR2). CARs can be first, second, third, or higher generation CARs. CARs can be bispecific for any two non-identical antigens, or specific for three or more non-identical antigens.

[0146] In certain aspects, the present disclosure provides systems and methods for generating T cells, including multi-TCR T cells, with enhanced anti-tumor phenotypes. In particular, the present disclosure provides methods for generating T cells from stem cells (e.g., HSCs) genetically modified with multiple transgenes, including a T cell receptor (TCR), a second TCR, and / or a chimeric antigen receptor (CAR), and at least one additional transgene. By starting with HSCs, the present system and methods exploit the self-renewal and cell differentiation capabilities of stem cells for the production of T cells with improved anti-tumor phenotypes. In particular, the present disclosure provides for introducing nucleic acids encoding a first TCR, a second TCR, and / or a CAR, and at least one additional transgene into CD34+ stem cells. The combined expression of the TCR and / or the TCR and CAR is useful for providing T cells with specific cancer cell targeting properties. Furthermore, by being endowed with at least one additional transgene, the T cells generated by the present method are equipped with a cargo (e.g., a cytokine) useful for the treatment of cancer when contacted with a target cancer cell.

[0147] For example, in a preferred embodiment, the method of the present invention includes introducing nucleic acid into HSC via lentiviral transduction, which can occur at multiple points during the manufacturing process. The introduction of one or more nucleic acids results in HSC expressing at least a first TCR, a second TCR and / or a CAR, and an additional transgene. The incorporation of the additional transgene is useful for providing therapeutic T cells with improved functional properties (e.g., improved cell proliferation, persistence, safety, and / or antitumor activity).

[0148] The one or more additional transgenes may include any one or more of a cytokine, a checkpoint inhibitor, an inhibitor of transforming growth factor beta signaling, an inhibitor of cytokine release syndrome, or an inhibitor of neurotoxicity. For example, transgenes encoding one or more of IL-2, IL-7, IL-15, IL-12, IL-18, or IL-21 may be provided.

[0149] Thus, in some instances, the methods of the invention provide for the production of T cells with improved proliferation and persistence capabilities, for example, by introducing nucleic acids encoding one or more of IL-2, IL-7, IL-1-15. In some instances, the methods may provide T cells with increased IFN-g production and thus improved T cell potency, for example, by introducing transgenes encoding one or more of IL-12, IL-18. In other instances, the methods of the invention are useful for enhancing naive T cell generation by introducing transgenes including IL-21. In some instances, the methods described herein provide for the generation of T cells with improved safety profiles, for example, by introducing inhibitors of IL-6, GM-CSF, or other mediators of cytokine release syndrome and neurotoxicity. The methods may provide CAR T cells with improved potency, for example, by providing a payload useful for combating the tumor microenvironment, via inhibitors of the TGF-B checkpoint.

[0150] Certain methods of the invention include a single in vitro activation step. In some instances, T cells are briefly activated with a reagent, for example for 1-3 days, and the activation reagent is often subsequently removed from the medium so as not to continuously stimulate the cells and thus exhaust them. After activation, the activated T cell population may rapidly expand, for example doubling in number every 24 hours. Some reagents may be added to promote proliferation. In some embodiments, the method includes a culture medium to which one or more of IL-7 / 15, IL-2, IL-2+21, IL-12, or IL-18 may be added.

[0151] In some examples, the single activation step includes a PMBC-based T cell activation. Thus, the activation step may include introducing aGC-loaded PBMCs, soluble anti-CD3 / 28 positive PBMCs, and soluble anti-CD2 / 3 / 28 positive PBMCs into T cells (or multi-TCR T cells). In some examples, the activation step includes an antigen-presenting cell (APC)-based T cell activation step. Thus, the activation step may include introducing T cells into APCs. The APCs may be genetically modified K562 cells expressing CD80-CD83-CD137L-CAR-antigens. The APCs may be APC+CD1d, and / or APC+CD1d+ / -aGC. In other examples, the activation step includes a feeder-free-based T cell activation step. The feeder-free-based T cell activation step may include introducing soluble antibodies, including anti-CD3, anti-CD28, anti-CD2 / 3 / 28, CD3 / 28, into T cells. In some embodiments, the T cell activation step comprises culturing the T cells in the presence of different cytokines IL-7 / 15, IL-2, IL-2+21, IL-12, IL-18 added to the activation growth culture medium.

[0152] The following examples provide useful illustrative protocols for producing T cells and multi-TCR T cells (e.g., iNKT and γδ T cells) from CD34+ cells provided by the methods of the invention. For further examples and discussion, see WO2019241400A1, which is incorporated by reference.

[0153] Example 1: CD34+ HSPC cell culture and lentiviral transduction Day -2: Pre-stimulation 1. The appropriate number of wells in a 24-well non-tissue culture treated plate (approximately 15 x 10 3 Cells / well or 0.1 x 10 6Coat 10 wells (it is recommended to seed 6 wells per aliquot) with 0.5 mL / well of 20 μg / mL Retronectin (RN) diluted in PBS. RN stock aliquots at 1 mg / mL can be stored at -20°C in 60 microliter aliquots. 2. Incubate at room temperature (RT) for 2 hours (h). 3. Aspirate the RNA and replace with 0.5 mL / well of 2% BSA diluted in PBS. Store 30% BSA aliquots at -20°C. 4. Incubate at room temperature for 30 minutes. 5. Aspirate and replace with 0.5 mL / well of PBS. 6. 0.1 x 10 cells of CD34+ cells following standard procedures 6 Thaw an aliquot into stem cell medium and spin at 300 g for 10 min. 7. Aspirate the supernatant, resuspend in stem cell medium, count using a hemocytometer, and record the cell count. In some instances, Applicants use 0.1×10 6 The cell counts in the aliquots were found to be too small to be reliable. 8. CD34+ cells were cultured in stem cell medium at 0.05 × 10 6 Dilute to cells / mL. 9. Aspirate PBS from RN-coated wells and add 300 µL cells / well (approximately 15 x 10 3 Cells / well) are seeded. 10. Incubate at 37°C, 5% CO2 for 12-18 hours.

[0154] Day -1: Transduction 1. Thaw concentrated lentiviral vector (LVV) and mix by gently pipetting (do not vortex or refreeze). 2. Prepare the transduction tubes. a. Calculate the amount of LVV sufficient to achieve an MOI of 100-200 and transfer the appropriate amount of LVV into a 1.5 mL tube. b. Add an appropriate amount of PGE2 to the same tube to give a final concentration of 10 nM in the entire culture volume. c. Add the appropriate amount of poloxamer to the same tube to achieve a final concentration of 1 μg / μL in the entire culture volume. 3. Add the contents of the transduction tubes to the appropriate culture wells and mix by gently rocking the plate. 4. Incubate the cells at 37° C., 5% CO2 for 24 hours.

[0155] Day 0: Harvest 1. Harvest the cells by gently pipetting them off the plate and transfer them to a conical tube. 2. Wash wells with an equal volume of cold X-VIVO-15 to remove any cells still attached to the plate and transfer to a conical tube. 3. Check under a microscope and collect all cells from the plate by further washing with cold X-VIVO-15 if necessary. 4. Spin at 300g for 10 min and aspirate the supernatant. 5. Proceed to Step 2 (i.e., Example 2).

[0156] Example 2: Generation of iNKT-CAR cells; Differentiation Days 0-14: Differentiation (duration: 2 weeks) 1. Coat the appropriate number of wells (1,000-2,000 cells / well or 12 wells / 15,000 cells is recommended) of a 12-well non-tissue culture treated plate with 1 mL / well of lymphoid differentiation coating medium (LDCM), such as Lymphoid Differentiation Material from STEMCELL under the trade name StemSpan, diluted 1:200 in PBS. Incubate at 4°C for 12-18 hours. 2. Aspirate the LDCM and add 2 mL / well of PBS. 3. Resuspend the transduced CD34+ cells collected in step 1 (i.e., Example 1) in Lymphoid Progenitor Cell Growth Medium (LPEM), such as Lymphoid Progenitor Cell Growth Medium sold under the trade name StemSpan by STEMCELL. 4. Adjust the cell concentration in LPEM to 1-2 x 10 3 Adjust to cells / mL. 5. Aspirate PBS from LDCM-coated plates. 6. Seed 0.75 mL cells / well onto LCDM coated plates. 7. Incubate the cells at 37°C, 5% CO2. 8. On day 3, add 0.25 mL / well of fresh LPEM and continue culturing. 9. On days 7 and 11, carefully remove less than 0.5 mL / well without disturbing the cells and replenish with 0.5 mL / well of fresh LPEM. 10. Continue culturing until day 14. 11. Proceed to step 3 (i.e., Example 3).

[0157] Example 3: Generation of iNKT-CAR cells; maturation 14th to 21st days onwards: Maturity (period: 1 to 2 weeks) 1. The appropriate number of wells (50-100 x 10) in a 6-well non-tissue culture treated plate 3 Coat the plates (recommended to seed 100 / well) with 2 mL / well of LDCM diluted 1:200 in PBS. Incubate at 4 °C for 12-18 h if prepared the day before seeding, or at 37 °C for 2 h if prepared on the day of seeding. 2. Aspirate the LDCM and add 4 mL / well of PBS. 3. On day 14, harvest and count cells using a cell viability counter (eg, a cell viability counter available from Beckman Coulter under the trade name Vi-Cell XR). a. Collect cells by gently pipetting them off the plate and transfer to a conical tube. b. Wash wells with 1 mL / 4 well of cold SFEM II to dislodge any cells still attached to the plate and transfer to a conical tube. c. Check under a microscope and harvest the cells from the plate, washing further with cold SFEM II if necessary. 4.0.2×10 6 An aliquot of cells is removed and plated into a 96-well V-bottom plate for flow staining. 5. Aliquot an appropriate amount of cells to seed for step 3 and pellet at 300g for 10 minutes. 6. Aspirate the supernatant. 7. The cells are cultured in T cell precursor maturation medium (TPMM), such as T cell precursor maturation medium provided by STEMCELL under the trade name StemSpan, at a concentration of 2.5 to 5 × 10 4 Resuspend at 100 cells / mL. 8. Aspirate PBS from LDCM-coated plates. Seed 9.2 mL cells / well onto LDCM coated plates. 10. Incubate the cells at 37°C, 5% CO2. 11. Pellet the remaining cells at 300g for 10 minutes. 12. Aspirate the remaining cells and place them at 2-5 × 10 cells in an appropriate amount of cryopreservation solution, for example, a cryopreservation solution sold by STEMCELL under the trade name CryoStor CS10. 6 Resuspend at 100 cells / mL. Aliquot into 13.1 mL / cryovial and freeze appropriately (e.g., in a -80°C freezer). Transfer to liquid nitrogen storage within 24 hours of freezing. 14. On day 17, add 2 mL / well of fresh TPMM and continue culturing. 15. On day 21, collect samples for flow cytometry by pipetting 100 μL from the cells in the center of the well and seeding into a 96-well V-bottom plate for flow staining. 16. Collect an additional 100 μL from the cells in the center of the well and count using a cell viability counter. 17. If TCR expression is >50%, CD4 / CD8 double positive expression >20% and cell size is shrinking (indicating HSC to T cell development), cells may be cryopreserved and donated for allogeneic therapy or optionally expanded as indicated in step 4. If these parameters are not met, continue culture with necessary feeding and passaging. Remove <2mL / well and replenish with 2mL / well of fresh TPMM every 3-4 days and passage the culture when it approaches confluence. This check is done again on days 24 / 25 and 28 until the above criteria are met.

[0158] Stage 4: Generation of iNKT-CAR cells; optional expansion: Days 21-28 (assuming criteria were met on day 21; adjust accordingly): Stimulation (duration: 1 week) 1. On day 21, harvest cells and count using a cell viability counter (record counts in associated excel sheet). a. Collect cells by gently pipetting them off the plate and transfer to a conical tube. b. Wash the wells with 2 mL of cold cell growth medium (EM) per 4 wells, for example cell growth medium provided by ThermoFisher under the trade name OpTmizer, to remove any cells still attached to the plate and transfer them to a conical tube. c. Check under a microscope and harvest the cells from the plate, washing further with cold EM if necessary. d.0.2×10 6 An aliquot of cells is removed and plated into a 96-well V-bottom plate for flow staining. e. Aliquot an appropriate amount of cells to seed for step 4 and pellet at 300 g for 10 min. f. Aspirate the supernatant. g.2×10 6 Resuspend cells at 1000 cells / mL in EM containing IL-7 and IL-15 at 10 ng / mL. 2. Depending on the desired stimulation method(s), follow a subset of the instructions below. Adjust the final concentration of iNKT-CAR cells to between 1 × 106 Fix to mL. A. No stimulation i. Culture the cells at 1 × 10 in EM medium containing IL-7 and IL-15 at 10 ng / mL. 6 Dilute to cells / mL. ii. Seed the cells and incubate at 37° C., 5% CO2. b.CD3 / soluble CD28 coat i.1. Coat plates with 23 μg / mL CD3 for 2 hours at 37° C. and wash with PBS before use. ii. 1 × 10 cells in EM containing IL-7 and IL-15 at 10 ng / mL 6 Dilute to cells / mL. iii. Add soluble CD28 to the cell suspension at 1 μg / mL. iv. Seed the cells and incubate at 37° C., 5% CO2. c. Soluble CD3 / Soluble CD28 and PBMCs i. Thaw human peripheral blood mononuclear cells (PBMCs) and irradiate at 6,000 rad. ii. Resuspend the PBMCs in EM containing IL-7 and IL-15 at 10 ng / mL. iii. Mix iNKT-CAR cells and PBMCs at a ratio of 1:2–3 (iNKT-CAR:PBMC) so that the final concentration of iNKT-CAR cells is 1 × 10 6 Adjust to cells / mL. iv. Add soluble CD3 and soluble CD28 to the cell suspension at 1 μg / mL. v. Seed the cells and incubate at 37° C., 5% CO2. d. Supplying a CD3 / CD28 T cell activator, such as the activator sold under the trade name ImmunoCult Human CD3 / CD28 T Cell Activator by StemCell Technologies. i. Culture the cells at 1 × 10 in EM medium containing IL-7 and IL-15 at 10 ng / mL. 6 Dilute to cells / mL. ii. Add CD3 / CD28 T cell activator to the cell suspension at 25 μL / mL. iii. Seed the cells and incubate at 37° C., 5% CO2. Supplying CD3 / CD28 / CD2 T cell activators, such as the activator sold under the trade name ImmunoCult Human CD3 / CD28 / CD2 T Cell Activator by e.StemCell Technologies. i. 1 × 10 cells in EM containing IL-7 and IL-15 at 10 ng / mL 6 Dilute to cells / mL. ii. Add CD3 / CD28 / CD2 T cell activator to the cell suspension at 25 μL / mL. iii. Seed the cells and incubate at 37° C., 5% CO2. f.aGC-supported PBMC i. Thaw human peripheral blood mononuclear cells (PBMCs). ii. 10 × 10 in EM containing 2 μg / mL aGC 6 Resuspend cells / mL and incubate for 1 h at 37 °C, 5% CO2. iii.aGC-loaded PBMCs were collected and irradiated at 6,000 rad. iv. Wash the cells at least twice with EM to remove unbound aGC. v. Resuspend PBMCs in EM containing IL-7 and IL-15 at 10 ng / mL. vi. Mix iNKT-CAR cells and PBMCs at a ratio of 1:2–3 (iNKT-CAR:PBMC) so that the final concentration of iNKT-CAR cells is 1 × 10 6 Adjust to cells / mL. vii. Seed the cells and incubate at 37° C., 5% CO2. g.K562-CD80-CD83-CD137L-A2ESO artificial antigen presenting cells (aAPC). i. aAPCs are harvested from culture and irradiated at 10,000 rad. ii. Mix iNKT-CAR cells and aAPCs at a ratio of 4:1 (iNKT-CAR:aAPC) so that the final concentration of iNKT-CAR cells is 1 × 10 6 Adjust to cells / mL. iii. Seed the cells and incubate at 37° C., 5% CO2. h.K562-CD80-CD83-CD137L-A2ESO-CD1d artificial antigen presenting cell (aAPC-CD1d). i. aAPCs are harvested from culture and irradiated at 10,000 rad. ii. Mix iNKT-CAR cells and aAPCs at a ratio of 4:1 (iNKT-CAR:aAPC) so that the final concentration of iNKT-CAR cells is 1 × 10 6 Adjust to cells / mL. iii. Seed the cells and incubate at 37° C., 5% CO2. i. aGC-bearing K562-CD80-CD83-CD137L-A2ESO-CD1d artificial antigen-presenting cells (aAPC-CD1d). i. Harvesting aAPCs from the culture. ii. 10x10 EM containing 2μg / mL aGC (see α-GalCer Prep SOP) 6 Resuspend at 200 cells / mL and incubate at 37°C, 5% CO2 for 1 h. iii. aGC-loaded aAPCs were collected and irradiated at 10,000 rad. iv. Mix iNKT-CAR cells and aAPCs at a ratio of 4:1 (iNKT-CAR:aAPC) so that the final concentration of iNKT-CAR cells is 1 × 10 6 Adjust to cells / mL. v. Seed the cells and incubate at 37° C., 5% CO2. 3. On day 24, count the cells using a cell counter (record the count in the associated excel sheet) and dilute the cells to 1 x 10 using EM containing IL-7 and IL-15 at 10 ng / mL. 6 Dilute to 100 cells / mL. Transfer to culture vessel if necessary. If PBMC or aAPC are utilized, the cell numbers obtained at this point may be more difficult to interpret, in which case carefully remove half of the culture medium without disturbing the cells and add an equal volume of fresh EM containing IL-7 and IL-15 at 10 ng / mL. This half-medium exchange is also performed if conditions without PBMC or aAPC do not require dilution. 4. On day 26, count the cells using a cell viability counter (record the count in the associated excel sheet) and dilute the cells to 1 x 10 using EM containing IL-7 and IL-15 at 10 ng / mL. 6 Dilute to 100 cells / mL. Transfer to culture vessel as needed. 5. On day 28, harvest cells and count using Vi-Cell (record counts in associated excel sheet). a.0.2×10 6 An aliquot of cells is removed and plated into a 96-well V-bottom plate for flow staining. b.0.2×10 6 An aliquot of cells is removed and seeded into a 96-well V-bottom plate for further flow staining. c.1×10 6 Aliquot the cells and dilute them to 1 x 10 in EM containing IL-7 and IL-15 at 10 ng / mL. 6 Dilute to 100 cells / mL and seed for longitudinal tracking (optional step, preferred after cell freezing is completed). d. Pellet the remaining cells at 300g for 10 minutes and aspirate the supernatant. e. Add 25-50 × 10 6 Resuspend at 100 cells / mL. f. Aliquot into 1 mL / cryovial, freeze appropriately, and transfer to liquid nitrogen storage within 24 hours of freezing.

[0159] Example 5: Generation of multi-TCR T cells from HSCs This example provides methods used to generate multi-TCR T cells from HSCs. The methods differ in the timing at which a second TCR is introduced to generate multi-TCR T cells. However, despite this difference in protocol, each method in this example generates multi-TCR T cells starting from HSCs in about 30 days. Additionally, all methods in this example include a cryopreservation step, allowing multi-TCR T cells to be generated quickly when needed and / or stored for use when needed.

[0160] Version 1 In a first version of the method, HSCs are differentiated into T cells (in this particular example, iNKT or γδ T cells) and an antigen-directed TCR is introduced into them. The general steps of this version of the method are shown in FIG.

[0161] Initially, the method begins in the same or similar manner as outlined in Examples 1-4 to generate TCR / CAR T cells. Thus, the method may include an initial stage 403 including a pre-stimulation step, a transduction step, and / or a harvesting step. The result of this initial transduction step is the introduction of a nucleic acid encoding a first TCR into HSCs. Again, similar to the methods of Examples 1-4, the method further includes a step 405 of differentiating the HSCs with the introduced first TCR into T cells (e.g., iNKT or γδ T cells). Similar to Examples 1-4, the T cells are subjected to a maturation step 407 and an expansion and / or activation step 409. In this example, after expansion, the single TCR T cells are cryopreserved. After cryopreservation and subsequent thawing, the T cells undergo a second round of transduction during which a second TCR is introduced into the T cells. In this case, the second TCR was introduced via lentiviral transduction. This second TCR specifically targets the ESO cancer-testis antigen.

[0162] The method results in the transformation of HSCs into iNKT cells or γδT cells that express, in addition to the iNKT / γδTCR, a second TCR that specifically targets a cancer antigen.

[0163] Version 2 The steps of the second version of the method are shown in Figure 5. The steps of the method proceed similarly to version 1, except that the method is flexible so that the final steps of expansion, activation, and / or cryopreservation are performed after the introduction of the second antigen-specific TCR, i.e., between days 21 and 34.

[0164] Version 3 The steps of the third version of the method are shown in FIG. 6. These steps are the same as the previous two methods. Thus, the method includes an initial stage 603 including a pre-stimulation step, a transduction step, and / or a harvesting step. The method further includes one or more steps 605 for differentiating HSCs with the introduced first TCR into T cells (e.g., iNKT or γδ T cells). As in Examples 1-4, the T cells are subjected to a maturation step 607 and an expansion and / or activation step 609. However, in this version of the method, the second target-specific TCR is introduced at about day 14, i.e., before or at the start of T cell maturation.

[0165] Example 6: Generation of γδ multi-TCR antigen-specific T cells HSCs were used to generate γδ T cells following the steps outlined in the method shown in Figure 6. Briefly, HSCs underwent lentiviral transduction to introduce a γδ TCR into the cells. The cells underwent differentiation step 605. Following differentiation, the resulting γδ ("GD-T") T cells underwent a second lentiviral transduction to introduce a TCR targeting the ESO cancer-testis antigen.

[0166] After maturation, the resulting multi-TCR T cells (bearing a γδTCR and an ESO-targeting TCR) were expanded / activated via contact with ESO antigen-presenting (ESOp-bearing) HLA-A2 PBMC.

[0167] In certain variations, PBMCs can be screened to determine whether they express activation / proliferation antigens at sufficiently high levels. Figure 7 shows the results of such screening. In the figure, PBMC line D4105 showed the highest HLA-A2 expression. Therefore, this line was selected for expanding multi-TCR T cells.

[0168] As shown in the right panel of Figure 8, multi-TCR T cells (GD-TCR / ESO-TCR) showed significant proliferation upon contact with ESOp-PBMCs. In contrast, cells without ESO-TCR ("NTD") showed little proliferation upon contact with PBCM.

[0169] To test the efficacy of multi-TCR T cells, target cells expressing HLA-A2-ESO were generated. Three such lines were generated. Two were derived from human ovarian cancer cell lines (SKOV3-luc and OVCAR3-luc) and one was derived from the peripheral blood of a multiple myeloma patient (MM.1S-luc). These lines were transduced with a transgene that allowed the cells to express the ESO antigen. Data for these test cell lines are shown in Figure 9.

[0170] These cells were then used to measure the cytotoxic potency and specificity of the multi-TCR T cells. Briefly, multi-TCR T cells were exposed to each test cell line and to the target cell parent line that was not transduced with the ESO antigen. Similarly, γδ T cells generated using the method of the invention but not transduced with a second ESO-specific TCR were exposed to the test cell line and the control line. All experiments were repeated, with the addition that the T cells were contacted with the aminobisphosphonate zoledronic acid (ZOL), which is known to contribute to the activation of γδ T cells. Figures 10 and 11 show the results of these in vitro killing assays.

[0171] Across all target cell lines, multi-TCR T cells (containing an ESO-specific TCR) showed greater cytotoxicity against ESO antigen-expressing target cells when compared to single-TCR T cells. This confirms that the second TCR was properly introduced into the γδ T cells and that the T cells have antigen-specific cytotoxicity. Furthermore, in all T cells (i.e., γδ T cells and multi-TCR T cells), contact with ZOL enhanced the killing capacity of the T cells. This is expected since ZOL is known to activate γδ T cells and multi-TCR T cells contain a γδ TCR.

[0172] Incorporation by Reference Throughout this disclosure, references and citations are made to other documents, such as patents, patent applications, patent publications, journals, books, articles, web content, etc. All such documents are incorporated herein by reference in their entirety for all purposes.

[0173] Equivalent Various modifications of the invention and many further embodiments thereof, in addition to those shown and described herein, will become apparent to those skilled in the art from the entire contents of this specification, including references to the scientific and patent literature cited herein. The subject matter of this specification contains important information, exemplification and guidance that can be adapted to the practice of this invention in its various embodiments and equivalents thereof.

Claims

1. 1. A method of generating T cells, comprising: carrying out a process of in vitro differentiation of hematopoietic stem cells (HSCs) into gamma delta (gd) T cells or invariant natural killer T (iNKT) cells comprising a first T cell receptor (TCR); and introducing at least a second TCR into said gdT cell or iNKT cell to generate a T cell with two distinct TCRs.

2. The method of claim 1, further comprising expanding the T cells after introducing the at least a second TCR into the gd T cells or iNKT cells.

3. The method of claim 1 , wherein the HSCs are differentiated into gd T cells.

4. 4. The method of claim 3, wherein the second TCR is an alpha beta (ab) TCR.

5. The method of claim 1 , wherein the HSCs are differentiated into iNKTs.

6. 5. The method of claim 4, wherein the second TCR is an alpha beta (ab) TCR.

7. 2. The method of claim 1, wherein the in vitro differentiation step comprises introducing into the HSC one or more nucleic acids encoding the first T cell receptor.

8. 8. The method of claim 7, wherein introducing the second TCR comprises introducing one or more nucleic acids encoding the second T cell receptor into the gdT cell or iNKT cell.

9. 8. The method of claim 7, wherein the in vitro differentiation step further comprises introducing one or more nucleic acids encoding at least one of a chimeric antigen receptor (CAR) and one or more transgenes.

10. 10. The method of claim 9, wherein the at least one or more transgenes comprise at least one of a cytokine, a checkpoint inhibitor, an inhibitor of transforming growth factor beta signaling, an inhibitor of cytokine release syndrome, an inhibitor of neurotoxicity, or other payload to make T cells more potent or less susceptible to exhaustion or rejection.

11. The method of claim 8, wherein the first and / or second TCR is a genetically modified TCR.

12. The method of claim 11, wherein the genetically modified TCR comprises one or more modifications to prevent TCR mispairing between the first TCR and the second TCR.

13. The method of claim 12, wherein the modifications include one or more of the mouse constant domains, disulfide bridges, and other dimerization domains.

14. The method of claim 1 , wherein the HSC is derived from a progenitor cell.

15. The method of claim 14, wherein the progenitor cells are pluripotent stem cells.

16. 15. The method of claim 14, wherein the in vitro process further comprises gene editing of the HSC or progenitor cells to make the T cells more potent or less susceptible to exhaustion or rejection.

17. The method of claim 1, wherein the second TCR is directed against a cancer germline antigen, a viral antigen, or a tumor-specific neo-antigen.

18. 10. The method of claim 1, wherein said step of introducing at least a second TCR comprises introducing a plurality of different TCRs.

19. 20. The method of claim 18, wherein each different TCR is directed to a different tumor-specific neo-antigen.

20. 20. The method of claim 19, wherein the neoantigen-reactive TCR is obtained or derived from peripheral blood T cells or tumor-infiltrating lymphocytes.

21. 2. The method of claim 1, wherein the step of introducing the second TCR comprises transferring one or more nucleic acids into the gd T cell or iNKT cell via non-viral methodologies of retroviral transduction, lentiviral transduction, or nucleotide transfer.

22. 2. The method of claim 1, further comprising in vitro activation and expansion of the T cells using HLA-matched or partially matched PBMCs carrying a peptide recognized by the second TCR.

23. 1. A method of treatment comprising: Obtaining HSCs; performing a process of in vitro differentiation of said HSCs into gamma delta (gd) T cells or invariant natural killer T (iNKT) cells comprising a first T cell receptor (TCR); introducing at least a second TCR into said gdT cell or iNKT cell; activating the resulting T cells to generate T cells with two distinct functional TCRs; and introducing said T cells into a subject, wherein said at least a second TCR is directed to a disease-associated antigen expressed on the surface of a cell in said subject.

24. 24. The method of claim 23, wherein the HSCs are obtained or derived from the subject.

25. 25. The method of claim 24, wherein the HSCs are allogeneic HSCs.

26. 24. The method of claim 23, wherein the method further comprises, after performing the in vitro differentiation step, obtaining data identifying one or more TCRs that target the disease associated antigen, and subsequently performing a step of introducing the at least a second TCR.

Citation Information

Patent Citations

  • TCR and peptides

    JP2020517308A

  • Genetically modified γδ T cells

    JP2021502815A

  • Recombinant receptor-expressing T cells, related polynucleotides, and methods

    JP2021520211A

  • TCR and peptides

    WO2020089433A2

  • Engineered off-the-shelf immune cells and methods of use thereof

    WO2020252303A1